Pharmaceutical formulations for subcutaneous administration of proteins
The hydrogel composed of chitosan A and statistical polysaccharide B solves the volume limitation and inflammatory risks of subcutaneous protein drug formulations, enabling large-volume delivery and sustained release, avoiding the use of hyaluronidase, and providing a safe and effective protein delivery solution.
Patent Information
- Application Number
- CN202380020097.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-03
- Filing Date
- 2023-02-03
- Publication Date
- 2024-11-08
AI Technical Summary
Existing subcutaneous protein drug formulations have volume limitations and inflammatory risks, making it difficult to achieve large-volume delivery and sustained release. Furthermore, formulations containing hyaluronidase may cause infertility risks.
A hydrogel composed of chitosan A and statistical polysaccharide B is formed by in-situ gelation under physiological conditions to create a biodegradable hydrogel that encapsulates proteins and enables their continuous release, thus avoiding the use of hyaluronidase.
This technology enables subcutaneous delivery of large-volume protein drugs, reduces the risk of inflammation, extends the injection interval, provides controlled and prolonged protein release, and avoids hyaluronidase-related toxicity.
Smart Images

Figure BDA0004976101530000034 
Figure BDA0004976101530000041 
Figure BDA0004976101530000061
Abstract
Description
Background Art
[0001] The pharmaceutical use of therapeutic proteins such as antibodies has increased over the past few years. Such therapeutic proteins are mainly administered via the intravenous (IV) route.
[0002] An alternative route of administration includes subcutaneous injection.
[0003] The advantage of subcutaneous injection is that it allows the practitioner to intervene in the patient in a relatively short time. In addition, the patient can be trained to perform the subcutaneous injection himself. During the maintenance dose, this self-administration is particularly useful because no hospital care is required (reducing medical resource utilization) and may have a positive impact on the patient's quality of life.
[0004] Although IV delivery can administer large volumes of drug directly into the bloodstream without volume limitations, injection of parenteral drugs into subcutaneous (SC) tissue is generally limited to volumes of less than 2 ml due to viscoelastic resistance in the SC tissue, due to back pressure generated during injection, and due to pain perception. Therefore, the volume that can be injected into the extracellular matrix of the SC tissue is limited.
[0005] For this reason, subcutaneous (SC) formulations of proteins require high protein concentrations in the final solution to be injected.
[0006] HERCEPTIN TM (trastuzumab) is a monoclonal antibody against the HER2 receptor (anti-HER2 antibody) sold in Europe in the form of a 150 mg lyophilized powder (containing antibody, α,α-trehalose dihydrate, L-histidine and L-histidine hydrochloride, and polysorbate 20), which should be reconstituted with water for injection for infusion to produce an injection dose of approximately 21 mg / ml.
[0007] ROCHE has developed Subcutaneous preparation, hereinafter referred to as SC. The SC preparation contains recombinant human hyaluronidase PH20 (rHuPH20), which is a recombinant human hyaluronidase that induces local and transient changes in the SC space through the degradation of hyaluronic acid, which is a naturally occurring glycosaminoglycan found throughout the body, which produces resistance to large amounts of fluid flow in the subcutaneous extracellular matrix and limits large-volume SC drug delivery. By degrading hyaluronic acid at the local injection site, hyaluronidase allows SC large amounts of fluid flow and promotes large-volume SC delivery.
[0008] However, high amounts of hyaluronidase may pose a risk of inflammation at the injection site. SC preparations are limited in the volume that can be accurately injected, and large amounts of SC preparations can produce inflammation. The maximum volume is approximately 6 mL.
[0009] To do this, the injections must be repeated approximately every two weeks. SC preparation.
[0010] In addition, by using circulating antibodies from immune macaques, it has been demonstrated that circulating antibodies that specifically recognize PH-20 bind to the surface of macaque sperm. Therefore, the effect of rHuPH20 antibodies on human fertility reduction cannot be ruled out, because antisperm antibodies may theoretically interfere with sperm maturation and motility, and in females, antisperm antibodies may hinder progress through the cervix and uterus, etc. Even though non-clinical studies conducted on SC rHuPH20 containing commercially available drugs did not show reproducible effects in several species, reversible infertility was observed in male and female guinea pigs that were immunized to produce hyaluronidase antibodies. The potential risk of reproducibility is still important, especially for drugs that are used for a long time in young non-cancer patients (multiple sclerosis, inflammatory bowel disease, etc.).
[0011] Another solution for local administration of antibodies is to prolong the release of the antibodies using suitable carrier materials. Several hydrogels based on synthetic or natural polymers have been proposed for prolonging the release of antibodies. Hydrogels are physical or chemical gels composed of polymer chains swollen with large amounts of water (about 70% of the total volume of the hydrogel). For example, hydrogel implants based on poly(ethylene-co-vinyl acetate) (EVAc) have been proposed. However, these implants are formed with harsh solvents that have the potential to degrade the antibodies, and the polymers are non-biodegradable, resulting in the patient requiring additional surgery to remove the implants. An anti-angiogenic antibody called bevacizumab (product name) targeting vascular endothelial growth factor (VEGF) has been examined. Genentech) is used for various clinical applications, including for the treatment of various cancers, for macular degeneration and other diseases of eyes. A study has examined the delivery of bevacizumab from mixed glycol chitosan and oxidized alginate hydrogels and may be used for ocular drug delivery, but releases completely after 3 days. In addition, there are also several biopolymers, such as alginate-chitosan hydrogels loaded with bevacizumab and control IgG. However, these hydrogels are only evaluated in vitro, and their biodegradability or biocompatibility are not studied. [Flecher et al., Materials Science and Engineering: C, 2016, 59.806-809].
[0012] Therefore, there remains a need to overcome the shortcomings of the prior art and to provide pharmaceutical compositions comprising a protein or combination of proteins that can be easily injected by an operator and that can provide a sustained release of the protein while causing little or no inflammation at the injection site.
[0013] Low inflammation is advantageous because it may allow for a shorter time interval between injections or for the injection area to be selected, which is often done with SC preparations are avoided because of the presence of hyaluronidase, such as the abdominal wall. Another purpose is to provide or similar antibodies (such as or other anti-HER2 antibody biosimilars), which do not require the presence of hyaluronidase and therefore do not have the risk of inflammation or toxicity associated with this enzyme. SUMMARY OF THE INVENTION
[0015] Embodiment E1 of the present disclosure is a pharmaceutical preparation of a pharmaceutically active protein, comprising:
[0016] - an effective amount of a protein or a combination of proteins,
[0017] - chitosan A comprising 90 to 100 mol % of D-glucosamine and 0 to 15 mol % of N-acetyl-D-glucosamine,
[0018] - at least one statistical polysaccharide B comprising D-glucosamine, N-acetyl-D-glucosamine and at least one sugar unit of formula I:
[0019]
[0020] in:
[0021] Rc is a hydrophilic group,
[0022] Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, and
[0023] - one or more pharmaceutically acceptable excipients.
[0024] Embodiment E2 of the present disclosure is a pharmaceutical formulation according to E1, wherein the pharmaceutical formulation forms a hydrogel at physiological pH and osmotic pressure.
[0025] Embodiment E3 of the present disclosure is a pharmaceutical formulation according to E1, wherein Rc is a group having an acidic nature, typically comprising a chemical functional group selected from the following: a carboxyl group (-COOH), a sulfonic acid group (-SO2OH), a phosphonate group (-PO(OH)2), a thiol group (-SH), an alcohol group (-OH) and a group comprising a chelating agent.
[0026] Embodiment E4 of the present disclosure is a pharmaceutical formulation according to E3, wherein Rc is a group comprising a chelating agent selected from DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetra(carbamoylmethyl)-1,4,7-triazacyclononane), DOTP ( 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonate), NOTP (1,4,7-tetra(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetra(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine, more preferably Rc is DOTAGA.
[0027] Embodiment E5 of the present disclosure is a pharmaceutical composition according to E1, wherein the statistical polysaccharide B has the general formula II:
[0028]
[0029] in:
[0030] Rc is a hydrophilic group,
[0031] Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur,
[0032] x is 0.01 to 0.5,
[0033] y is 0.05 to 0.5,
[0034] The ratio y / x is greater than 0.2, preferably greater than 1,
[0035] The sum of x+y is greater than 0.1.
[0036] Embodiment E6 of the present disclosure is a pharmaceutical formulation according to E5, wherein Rc is a group having an acidic nature, typically selected from a group comprising a carboxyl group (-COOH), a sulfonic acid group (-SO2OH), a phosphonate group (-PO(OH)2), a thiol group (-SH), an alcohol group (-OH) and a group comprising a chelating agent.
[0037] Embodiment E7 of the present disclosure is a formulation according to E6, wherein Rc is a group comprising a chelating agent selected from DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetra(carbamoylmethyl)-1,4,7-triazacyclononane), DOTP (1 , 4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonate), NOTP (1,4,7-tetra(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetra(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine, more preferably Rc is DOTAGA.
[0038] Embodiment E8 of the present disclosure is a pharmaceutical formulation according to E1, wherein the statistical polysaccharide B has the general formula III:
[0039]
[0040] in:
[0041] -Rc1 and Rc2 are different and are hydrophilic groups,
[0042] - Z1 and Z2 are identical or different and are linkers, said linker being a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, said chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur,
[0043] -x is 0.01 to 0.5, preferably 0.01 to 0.1, and more preferably 0.05 to 0.1,
[0044] -y is 0.01 to 0.5, preferably 0.05 to 2
[0045] -Z is 0 to 0.2,
[0046] - the ratio y / x is greater than 0.2, preferably greater than 1,
[0047] -The sum of x+y is greater than 0.1.
[0048] Embodiment E9 of the present disclosure is a pharmaceutical formulation according to E8, wherein Rc1 and Rc2 are groups having acidic properties, typically selected from groups comprising a carboxyl group (-COOH), a sulfonic acid group (-SO2OH), a phosphonate group (-PO(OH)2), a thiol group (-SH), an alcohol group (-OH) and a group comprising a chelating agent.
[0049] Embodiment E10 of the present disclosure is a pharmaceutical formulation according to E9, wherein Rc1 and / or Rc2 is a chelating agent, and Rc1 and / or Rc2 are preferably selected from DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetra(carbamoylmethyl)-1,4,7-triazacyclononane), DOTP (1, 4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonate), NOTP (1,4,7-tetra(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetra(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine, more preferably Rc1 is DOTAGA and Rc2 is DFO or Bz-DFO.
[0050] Embodiment E11 of the present disclosure is a pharmaceutical formulation according to any one of the preceding embodiments, wherein Z, Z1 and Z2 are independently selected from a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, an alkyl chain containing 1 to 12 carbon atoms, the chain being linear or branched, and an alkenyl chain containing 2 to 12 carbon atoms, the chain being linear or branched, the alkyl and alkenyl chains being optionally C6-C 10 The alkyl and alkenyl chains may be substituted by one or more atoms or groups selected from -OR', -COOR', -SR', -NR'2, wherein each R' is independently substituted by one or more aryl groups and / or one or more heteroatoms or groups selected from -O-, -S-, -C(O)-, -NR'-, -C(O)NR'-, -NR'-C(O)-NR'-, -NR'-C(O)-O-, -OC(O)NR', -C(S)NR'-, -NR'-C(S)-, -NR'-C(S)-NR', and the alkyl and alkenyl chains may be substituted by one or more atoms or groups selected from -OR', -COOR', -SR', -NR'2, wherein each R' is independently substituted by one or more aryl groups and / or one or more heteroatoms or groups selected from -O-, -S-, -C(O)-, -NR'-C(O)-NR'-, -NR'-C(O)-O-, -OC(O)NR', -C(S)NR'-, -NR'-C(S)-, -NR'-C(S)-NR' R' is independently H or an alkyl group in C1-C6, preferably Z, Z1 and Z2 are each independently selected from a single bond, an alkyl chain containing 1 to 12 carbon atoms, the chain being linear or branched, and the alkyl chain may be interrupted by one or more aryl groups in C6-C10 and / or one or more heteroatoms or groups selected from -O-, -S-, -C(O)-, -NR'-, -C(O)NR'-, -NR'-C(O)-, -C(S)NR'-, -NR'-C(S)-, -NR'-C(S)-NR', and each R' is independently H or an alkyl group in C1-C6.
[0051] Embodiment E12 of the present disclosure is a pharmaceutical formulation according to E11, wherein Z, Z1 and Z2 are each an alkyl chain containing 1 to 12 carbon atoms.
[0052] Embodiment E13 of the present disclosure is a pharmaceutical formulation according to E11, wherein Z, Z1 and Z2 are each a polyethylene glycol (PEG) moiety.
[0053] Embodiment E14 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E13, wherein the statistical polysaccharide B has an average molecular weight of 100 kDa to 1000 kDa, more advantageously 200 kDa to 750 kDa, even more advantageously 250 kDa to 500 kDa and most advantageously 300 kDa to 400 kDa.
[0054] Embodiment E15 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E14, which is for subcutaneous administration.
[0055] Embodiment E16 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E15, wherein the hydrogel releases the protein over a period of 10 to 100 days, preferably 20 to 65 days, from the date of administration.
[0056] Embodiment E17 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E16, wherein the viscosity of the formulation is 10 to 500 Pa.s, as measured by rotational rheometry in a planar cone geometry at 0.001 s -1 To 0.01s -1 , for example 0.001s -1 To 0.01s -1 , especially 0.01s -1 Shear rate measurement.
[0057] Embodiment E18 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E17, wherein the pH of the formulation is 5.0 to 6.5, preferably 5.5 to 6.0.
[0058] Embodiment E19 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E18, wherein the osmotic pressure of the formulation is 50mOsm / L to 600mOsm / L, preferably 100mOsm / L to 600mOsm / L, more preferably 250mOsm / L to 450mOsm / L, or 50mOsm / L to 300mOsm / L, preferably 50mOsm / L to 250mOsm / L.
[0059] Embodiment E20 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E19, comprising:
[0060] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A, and 10 to 200 g / l, preferably 20 to 100 g / l of polysaccharide B, and
[0061] - 1 g / l to 200 g / l, preferably 50 to 100 g / l of protein or a combination of proteins.
[0062] Embodiment E21 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E20, wherein the protein has a molecular weight of 10 kDa to 250 kDa, preferably 20 kDa to 250 kDa, preferably 100 kDa to 250 kDa, preferably 120 kDa to 250 kDa, preferably 150 kDa to 250 kDa.
[0063] Embodiment E22 of the present disclosure is a pharmaceutical formulation according to any one of embodiments E1 to E21, wherein the protein or protein combination is selected from the group consisting of antibodies, enzymes, fusion proteins, and combinations thereof.
[0064] Embodiment E23 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E22, wherein the formulation does not contain hyaluronidase.
[0065] Embodiment E24 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E23, wherein the protein or protein combination comprises an antibody or an antigen-binding fragment of an antibody.
[0066] Embodiment E25 of the present disclosure is a pharmaceutical formulation according to E24, wherein the antibody or antibody combination is selected from the group consisting of: (i) a chimeric, human or humanized antibody, and (ii) an antibody-drug conjugate.
[0067] Embodiment E26 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E25, wherein the protein or protein combination is an antibody or antibody combination that binds to an antigen selected from HER2 and CD20.
[0068] Embodiment E27 of the present disclosure is a pharmaceutical formulation according to E27, wherein the antibody is selected from the group consisting of trastuzumab, rituximab and pertuzumab, or a combination thereof.
[0069] Embodiment E28 of the present disclosure is a pharmaceutical formulation according to any one of E27 or E28, wherein the formulation comprises a combination of Trastuzumab and Pertuzumab.
[0070] Embodiment E29 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E28, further comprising at least one pharmaceutically acceptable excipient selected from solvents, stabilizers, surfactants, buffers, antimicrobial preservatives, protectants, antioxidants, chelating agents and fillers.
[0071] Embodiment E30 of the present disclosure is a pharmaceutical formulation according to any one of E1 to E30, wherein the formulation comprises:
[0072] 1 g / l to 200 g / l, preferably 50 to 100 g / l of an antibody or a combination of antibodies, in particular trastuzumab, rituximab, pertuzumab or daratumumab, or a combination of trastuzumab and pertuzumab,
[0073] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A, and
[0074] 20 to 400 g / l, preferably 20 to 300 g / l of statistical polysaccharide B, and
[0075] At least one excipient selected from the group consisting of:
[0076] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0077] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate
[0078] o 5 to 25 mM of an antioxidant, preferably methionine.
[0079] Embodiment E31 of the present disclosure is a kit, characterized in that it comprises:
[0080] - at least one first container containing chitosan A and a polysaccharide B as defined in any one of E1 to E12,
[0081] - at least one second container containing a protein or a combination of proteins as defined in any of E22 to E29.
[0082] Embodiment E32 of the present disclosure is a kit according to E31 for preparing a ready-to-use injectable formulation according to the present disclosure.
[0083] Embodiment E33 of the present disclosure is a pharmaceutical formulation according to any one of claims E1 to E31 or a kit according to any one of E32 or E33 for use in the treatment of cancer, typically breast cancer or gastric cancer, or a non-malignant disease.
[0084] Embodiment E34 of the present disclosure is a method of treating cancer in a subject in need thereof, the method comprising subcutaneously administering in the subject a therapeutically effective amount of an antibody or combination of antibodies according to any one of E27 to E29 that binds to an antigen selected from HER2 and CD20. BRIEF DESCRIPTION OF THE DRAWINGS
[0085] Figure 1 Shown is a gel formed from a solution of MEX-CD2-I-tmb in Hemosol B0.
[0086] Figure 2 shows the in situ gelation of MEX-CD2-I-tmb solution with fluorescent labeling solution ( Figure 2 A), and the gel obtained after complete gelation in physiological serum ( Figure 2 B).
[0087] Figure 3 Shown is the stability range of MEX-CD2-I solutions as a function of pH and osmotic pressure.
[0088] Figure 4Shown is the time tracking of mouse body weight after subcutaneous injection of 200 μL of MEX-CD2-I-tmb solution loaded with 100 g / L trastuzumab antibody. N=9 mice.
[0089] Figure 5 Shown is hematoxylin and eosin (H&E) labeling on day 20 after subcutaneous injection of 200 μL of MEX-CD2-I-tmb solution (corresponding to a dose of 15 mg trastuzumab).
[0090] Figure 6 The results show that the subcutaneous injection of 200 μL MEX-CD2-I-tmb solution (corresponding to a dose of 15 mg trastuzumab) is comparable to the subcutaneous injection of Roche SC Time course of the presence of trastuzumab antibodies in plasma after formulation (corresponding to a dose of 15 mg trastuzumab).
[0091] Figure 7 Monitoring of the presence of fluorescently labeled MEX-CD2-I solution after injection is shown.
[0092] Figure 8 Longitudinal monitoring of antibody-loaded hydrogel degradation by fluorescence imaging is shown.
[0093] Fig. 9 The percentage of fluorescence over time compared to the initial fluorescence of the hydrogel is shown.
[0094] Fig.10 The percentage of gadolinium present in each organ / region compared to the maximum amount of gadolinium complexed in the gel initially for solutions with and without trastuzumab is shown.
[0095] Fig.11 Shown are (A) T1 MRI signals of hydrogel-loaded trastuzumab implanted in the neck (200 μL) of mice (n=3) - the dashed line represents the hydrogel outline - and (B) volume curves of trastuzumab-loaded hydrogels of different volumes and ratios.
[0096] Fig.12 Comparison of injection volumes of subcutaneously implanted hydrogel-loaded trastuzumab is shown. Subcutaneous implantation (n=3) of 50 μL and 200 μL of hydrogel-loaded trastuzumab (100 G / L trastuzumab) provided identical degradation profiles.
[0097] Fig.13 Shown is immunofluorescence staining of pro-inflammatory neutrophils located at the injection site 5 days after hydrogel-loaded trastuzumab implantation.
[0098] Fig.14Cumulative release of monoclonal antibodies (trastuzumab or rituximab) and monoclonal antibody combinations (trastuzumab and pertuzumab) in PBS at 37°C is shown.
[0099] Fig.15 Shown are the results of the cumulative release of monoclonal antibody fragments (Fab'2 and VHH) in PBS at 37°C.
[0100] Fig.16 Shown are SEM images at different magnifications of gels formed from polymer solutions with and without trastuzumab in PBS solution. DETAILED DESCRIPTION OF THE INVENTION
[0102] A first aspect of the present disclosure is a pharmaceutical preparation comprising:
[0103] - a therapeutically effective amount of a protein or a combination of proteins,
[0104] - chitosan A comprising 90 to 100 mol % of D-glucosamine and 0 to 15 mol % of N-acetyl-D-glucosamine,
[0105] - at least one statistical polysaccharide B comprising D-glucosamine, N-acetyl-D-glucosamine and at least one sugar unit of formula I:
[0106]
[0107]
[0108] in:
[0109] Rc is a hydrophilic group,
[0110] Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, and
[0111] - one or more pharmaceutically acceptable excipients.
[0112] Polysaccharides
[0113] According to the present disclosure, "chitosan" means a natural polymer of the polysaccharide type of D-glucosamine (GlcN) or the copolysaccharide type consisting of random distribution (statistical copolysaccharide) or non-random distribution (block copolysaccharide) of D-glucosamine and N-acetyl-D-glucosamine (GlcNAc) linked by β(1→4) type glycosidic bonds.
[0114] According to the present disclosure, the average molecular weight Mw of polysaccharides such as chitosan A and polysaccharide B is measured by size exclusion chromatography, which is described in "Physico-chemical studies of the gelation of chitosan in ahydroalcoholic medium" A. MONTEMBAULT, C. VITON, A. DOMARD, Biomaterials, 26(8), 933-943, 2005.
[0115] The proportion of N-acetyl-D-glucosamine was calculated by using H 1 NMR was calculated according to Hirai's method (A. HIRAI, HODANI, A. NAKAJIMA, Polymer Bulletin, 26 (1), 87-94, 1991).
[0116] According to the present disclosure, the crystallinity ratio refers to the proportion of crystalline material. Regarding polysaccharides, the crystallinity ratio is usually measured using X-ray diffraction (Alexander, LE, 'X-ray Diffraction Methods in Polymer Science', Wiley-Interscience, New York, 1969, p. 137).
[0117] Chitosan A
[0118] The pharmaceutical preparation of the present disclosure comprises chitosan A. The preparation may have:
[0119] - a proportion of crystallinity of chitosan A of at least 10% by weight relative to the total dry mass of the preparation, and
[0120] -The crystal size of chitosan A is less than 20 nm.
[0121] The crystallinity ratio of chitosan A may be 10 to 25%. The crystals of chitosan A serve as physical cross-linking junctions necessary for forming a gel. The crystal size may be, for example, 1 to 20 nm.
[0122] Advantageously, chitosan A has an average molecular weight Mw of 100 to 1000 kg / mol, preferably 200 to 700 kg / mol.
[0123] According to a preferred embodiment, chitosan A has 1 mol% to 9 mol% N-acetyl-D-glucosamine, preferably 2 mol% to 8 mol%, more preferably 3 mol% to 7 mol%, even more preferably 4 mol% to 6 mol%, most preferably 5 mol%.
[0124] Statistical Polysaccharide B
[0125] The formulation comprises statistical polysaccharide B.
[0126] Advantageously, the statistical polysaccharide B has an average molecular weight of 100 kDa to 1000 kDa, more advantageously 200 kDa to 750 kDa, even more advantageously 250 kDa to 500 kDa, most advantageously 300 kDa to 400 kDa.
[0127] Preferably, Rc is a group having acidic properties, typically selected from groups containing carboxyl (-COOH), sulfonic acid (-SO2OH), phosphonate (-PO(OH)2), thiol (-SH), alcohol (-OH) and groups containing chelating agents.
[0128] In the specific embodiment where Rc is a chelating agent, Rc can be selected from DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetra(carbamoylmethyl)-1,4,7-triazacyclononane), DOTP (1,4,7,10- Tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonate), NOTP (1,4,7-tetrakis(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetrakis(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine, more preferably Rc is DOTAGA.
[0129] The chelating agent of polysaccharide B preferably participates in the gelation of the polysaccharide mixture and imparts swelling properties to the hydrogel. In addition, the chelating agent preferably promotes the formation of a hydrogel containing non-crystalline regions, which may lead to good biodegradability of the hydrogel.
[0130] Chitosan A promotes the formation of crystals responsible for the gel state in the material in contact with body fluids.
[0131] According to the present disclosure, the expression "polysaccharide mixture" refers to chitosan A and polysaccharide B.
[0132] In one embodiment, the statistical polysaccharide B has the following general formula II:
[0133]
[0134] in:
[0135] Rc is a hydrophilic group,
[0136] Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur,
[0137] x is 0.01 to 0.5,
[0138] y is 0.05 to 0.5,
[0139] The ratio y / x is greater than 0.2, preferably greater than 1,
[0140] The sum of x+y is greater than 0.1.
[0141] In some embodiments, the statistical polysaccharide B comprises two different units of formula I. In these embodiments, the statistical polysaccharide B has the following general formula III:
[0142]
[0143] in:
[0144] -R c1 and R c2 Different, and is a hydrophilic group,
[0145] - Z1 and Z2 are identical or different and are linkers, said linker being a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, said chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur,
[0146] -x is 0.01 to 0.5, preferably 0.01 to 0.1, and more preferably 0.05 to 0.1,
[0147] -y is 0.01 to 0.5, preferably 0.05 to 2
[0148] -Z is 0 to 0.2,
[0149] - the ratio y / x is greater than 0.2, preferably greater than 1,
[0150] -The sum of x+y is greater than 0.1.
[0151] Preferably, Rc1 and Rc2 are groups having acidic properties, typically selected from groups containing carboxyl groups (-COOH), sulfonic acid groups (-SO2OH), phosphonate groups (-PO(OH)2), thiol groups (-SH), alcohol groups (-OH) and groups containing chelating agents.
[0152] In the embodiment where Rc1 and / or Rc2 is a chelating agent, Rc1 and / or Rc2 are preferably selected from DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetra(carbamoylmethyl)-1,4,7-triazacyclononane), DOTP (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), Heterocyclododecane-1,4,7,10-tetrakis(methylenephosphonate), NOTP (1,4,7-tetrakis(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetrakis(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine, more preferably Rc1 is DOTAGA and Rc2 is DFO or Bz-DFO.
[0153] The precursor of the Bz-DFO chelating group is p-NCS-Bz-DFO (Cas No: 1222468-90-7), whose NCS group generates thiourea when reacting with amines, and therefore is no longer NCS once grafted onto a molecule such as polysaccharide B.
[0154] Rc, Rc1 and Rc2 are chelating groups
[0155] As described above, the Rc groups in Formula I and Formula II and the Rc1 and Rc2 groups in Formula III can be chelating groups. In an embodiment, Rc, Rc1 and Rc2 are chelating groups that can chelate one or more metals by forming a complex.
[0156] In one embodiment, less than 10%, preferably less than 5%, of the chelating groups are chelated with cations, especially metal cations. In case the chelating groups are in free form, the capture of metals is good and the polysaccharide B also has a strongly hydrophilic behavior, which means good swelling properties.
[0157] Each of Rc, Rc1 and Rc2 may contain one or more coordination sites. Preferably, the coordination sites are nitrogen or oxygen atoms. Advantageously, each of Rc, Rc1 and Rc2 includes 4 to 8 coordination sites, more advantageously 6 to 8 coordination sites, and even more advantageously each of Rc, Rc1 and Rc2 includes 8 coordination sites.
[0158] In the present disclosure, coordination site means a unique function capable of chelating a metal. For example, an amine functional group represents one coordination site by forming a coordinate bond between the nitrogen of the amine and the metal, and a hydroxamic acid functional group also represents one coordination site by forming a coordinate bond between the oxygen of the carbonyl moiety and the metal and by forming a covalent bond between the oxygen of the N-oxide moiety and the very same metal, the coordination sites forming a 5-linked ring.
[0159] Z, Z1 and Z2
[0160] As mentioned above, Z, Z1 and Z2 are linkers, which are single bonds, hydrocarbon chains containing 1 to 12 carbon atoms, which chains are linear or branched, saturated or unsaturated, and optionally contain one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur.
[0161] The choice of Z, Z1 and Z2 depends essentially on Rc, Rc1 and Rc2 and on the metal to be finally chelated. In practice, notably for steric reasons, Rc, Rc1 and Rc2 may be more or less close to the 6-linked ring.
[0162] In some embodiments, Z, Z1 and Z2 are independently selected from a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, an alkyl chain containing 1 to 12 carbon atoms, the chain being linear or branched, and an alkenyl chain containing 2 to 12 carbon atoms, the chain being linear or branched, the alkyl and alkenyl chains being optionally C6-C 10The alkyl and alkenyl chains may be substituted by one or more atoms or groups selected from -OR', -COOR', -SR', -NR'2, and each R' is independently H or an alkyl group in C1-C6.
[0163] Advantageously, Z, Z1 and Z2 are each independently selected from a single bond, an alkyl chain containing 1 to 12 carbon atoms, the chain being linear or branched, the alkyl chain being C6-C 10 The alkylene group is optionally substituted with an aryl group selected from -O-, -S-, -C(O)-, -NR'-, -C(O)NR'-, -NR'-C(O)-, -C(S)NR'-, -NR'-C(S)-, -NR'-C(S)-NR', and each R' is independently H or an alkyl group in C1-C6.
[0164] In one specific embodiment, Z, Z1 and Z2 are each an alkyl chain containing 1 to 12 carbon atoms.
[0165] In another specific embodiment, each of Z, Z1 and Z2 is a polyethylene glycol (PEG) moiety.
[0166] Method for preparing polysaccharide B
[0167] Polysaccharide B can be obtained by a method comprising the following three consecutive steps:
[0168] - Step 1: Dissolve chitosan in an acidic solution with a pH of 4 to 5;
[0169] - Step 2: Acetylation of part of the amine functional groups of the chitosan dissolved in step 1;
[0170] - Step 3: functionalizing at least a portion of the amine functional groups remaining after step 2.
[0171] Step 3 can be subdivided into several sub-steps, in particular when Z, Z1 and / or Z2 are hydrocarbon chains as defined above.
[0172] In the embodiment where Z, Z1 and / or Z2 are hydrocarbon chains as defined above, step 3 may comprise a subsequent step 3-1 consisting in grafting said hydrocarbon chain onto at least a portion of the remaining amine functional groups after step 2, and a subsequent subsequent step 3-2 consisting in grafting Rc, Rc1 and / or Rc2. Alternatively, step 3 does not comprise a subsequent step. In this alternative, said hydrocarbon chain is coupled to Rc, Rc1 and Rc2, in which case said step 3 is performed with a molecule comprising Rc, Rc1 or and said hydrocarbon chain.
[0173] In an alternative manner, polysaccharide B can be obtained starting from chitosan having an appropriate number of N-acetyl-D-glucosamine units. In this alternative, it is not necessary to carry out step 2 above, therefore, in this alternative, the method for obtaining polysaccharide B comprises at least two of the following consecutive steps:
[0174] - Step 1b: dissolving chitosan comprising N-acetyl-D-glucosamine units in an acidic solution at a pH of 4 to 5;
[0175] - Step 2b: Functionalization of at least part of the amine functional groups of said chitosan comprising N-acetyl-D-glucosamine units dissolved in step 1.
[0176] In the same way as step 3 above, step 2b can be subdivided into several sub-steps, especially when Z, Z1 and / or Z2 are hydrocarbon chains as defined above.
[0177] In the embodiment where Z, Z1 and / or Z2 are hydrocarbon chains as defined above, step 2b may comprise a subsequent step 2b-1 consisting in grafting the hydrocarbon chains to at least a portion of the amine functional groups, and a subsequent subsequent step 2b-2 consisting in grafting Rc, Rc1 and / or Rc2 to the hydrocarbon chains. Alternatively, step 2b does not comprise a subsequent step. In this alternative, the hydrocarbon chains are coupled to Rc, Rc1 and Rc2, in which case step 2b is performed with a molecule comprising Rc, Rc1 or and the hydrocarbon chains.
[0178] Polysaccharide content
[0179] The content of chitosan A in the pharmaceutical preparation of the present disclosure is preferably 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A.
[0180] The content of statistical polysaccharide B in the pharmaceutical preparation of the present disclosure is preferably 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B.
[0181] The weight ratio of chitosan A / polysaccharide B is preferably 5 / 1 to 1 / 5, preferably 1 / 1 to 1 / 5, preferably 1 / 1 to 1 / 3.
[0182] In one embodiment, the weight ratio of chitosan A / polysaccharide B is about 1 / 2, preferably 1 / 2.
[0183] In one embodiment, the pharmaceutical composition comprises 2% to 10%, preferably 2%, 3%, 4%, 5%, 6%, 7% or 8% to 10%, more preferably 3% to 8% of chitosan A and polysaccharide B, the % being expressed by weight relative to the weight of the pharmaceutical composition.
[0184] Viscosity
[0185] The pharmaceutical formulations of the present disclosure can be easily injected into tissues due to their rheological properties while being able to form biodegradable hydrogels in vivo that entrap proteins and enable controlled and prolonged release of the proteins in tissues.
[0186] The pharmaceutical preparation of the present disclosure is preferably in the form of a liquid preparation, more preferably in the form of a liquid injectable preparation.
[0187] According to the present disclosure, "liquid injectable formulation" means a liquid formulation having a sufficiently low viscosity to allow good syringeability through a gauge needle.
[0188] The term "injectability" or "syringability" as generally used herein refers to the injectable property of the pharmaceutical formulation of the present disclosure through a syringe equipped with an 18-32 gauge needle, preferably a 20-27 gauge needle.
[0189] The pharmaceutical formulations of the present disclosure preferably have a viscosity of 10 to 500 Pa.s, preferably 10 to 300 Pa.s, more preferably 15 to 250 Pa.s, as measured by rotational rheometry in a flat cone geometry at room temperature at a speed of 0.01 to 0.001 s. -1 , for example 0.001s -1 or 0.01s -1 , preferably 0.01s -1 Shear rate measurement.
[0190] In one embodiment, the viscosity of the pharmaceutical formulation is 10 to 80 Pa.s, preferably 10 to 50 Pa.s, more preferably 10 to 30 Pa.s, or the viscosity is 80 to 250 Pa.s, preferably 80 to 120 Pa.s, for example about 100 Pa.s.
[0191] The term "viscosity" refers to the resistance of a substance (usually a liquid) to flow. Viscosity is related to the concept of shear force; it is understood as the effect of shear forces exerted on each other or other surfaces as different layers of a fluid move relative to each other. The unit of viscosity is Ns / m 2 , called Pascal-second (Pa.s).
[0192] The viscosity of the pharmaceutical preparation of the present disclosure is usually measured in a plane cone geometry by rotational rheometry using a viscometer with imposed deformation (such as an advanced rheometer AR2000 from TAinstruments). In short, the fluid is subjected to shear between two surfaces, one is fixed and the other rotates around its axis. In fact, the two surfaces are usually cones and planes. The shear gradient is determined by the geometry of the surface on the one hand and by the rotation speed on the other hand. The shear stress is calculated by the measured value of the torque transmitted by the sample to be characterized. A detailed description of this method can be found in El Kissiet al, Rheology, 10, 13-39 (2006). In the present invention, the measurement is carried out at room temperature (e.g., about 20°C, preferably about 25°C), and 4° and 25mm cone plane geometry are usually used with 0.01 to 0.001s -1 , for example 0.01s -1 or 0.001s -1 , especially 0.01s -1 Alternatively, the measurement can be carried out at room temperature (e.g. about 20°C, preferably about 25°C) using a C35 / 2° Ti L conical plane geometry, which is carried out by 10 -2 Up to 10 3 s- 1 Flow scanning linear studies (viscosity measurement method (ii)) are performed at a scanning shear rate of about 0.001s / s. The viscosity measurement method (i) is preferably performed using an advanced rheometer AR2000 from TA instruments, which has a 4° and 25 mm flat cone geometry. The viscosity measurement method (ii) is preferably performed using a RheoStress 600 rheometer from Thermo Scientific HAAKE, using a C35 / 2° Ti L cone flat geometry. In the viscosity measurement method (i), the viscosity values can be measured at relatively low shear rates. However, it can be noted that for low viscosity solutions, for example for solutions with a viscosity below 20 Pa.s, the viscosity values can be measured at a shear rate of about 0.001s / s according to the viscosity measurement method (i). -1 The viscosity values measured at shear rate values of 0.001 s may be distorted in some cases because they correspond to the measurement limit of the machine. For such low-viscosity solutions, the viscosity measurement is preferably carried out according to viscosity method (i) at a shear rate higher than 0.001 s -1 The shear rate is usually about 0.01s -1 The shear rate is preferably 0.01s -1 or according to viscosity measurement method (ii).
[0193] Before the measurement, set the zero deviation and calibrate the inertial and rotational mapping of the instrument. Then spread the sample on a flat surface and set the deviation from the conical plane geometry to 116 microns in the viscosity measurement method (i) or to 105 microns in the viscosity measurement method (ii). Advantageously, remove excess sample with a spatula to limit edge effects.
[0194] The higher the viscosity of the drug formulation, the more localization of the drug formulation within the tissue at the injection site prior to formation of a hydrogel.
[0195] In the pharmaceutical preparation of the present disclosure, the mixture of chitosan A and polysaccharide B is preferably present in the pharmaceutical preparation in a dissolved form, meaning that at least 90%, preferably at least 95% of the mixture is in a dissolved form relative to the total weight of the mixture in the pharmaceutical preparation, % being expressed as the weight of the mixture in dissolved form.
[0196] The presence of the polysaccharide mixture in dissolved form in the pharmaceutical formulations of the present disclosure enables the pharmaceutical formulation to be in the form of a viscous solution that is liquid enough to be injected through a variety of needles commonly used in the medical field.
[0197] In other words, the pharmaceutical formulations of the present disclosure are not in the form of a solid hydrogel, as in the case of an implantable hydrogel.
[0198] Biodegradable and biocompatible hydrogels
[0199] The polysaccharide mixture of the pharmaceutical preparation of the present disclosure is capable of in situ gelation under physiological conditions, particularly at physiological pH and osmotic pressure, thereby forming a hydrogel.
[0200] In the pharmaceutical preparation of the present invention, chitosan A, polysaccharide B and protein or protein combination are intimately mixed. Thus, the in situ gelation of the polysaccharide mixture results in encapsulation of the protein or protein combination present in the medicament of the present disclosure into the hydrogel.
[0201] The hydrogel formed in the tissue is biodegradable and biocompatible. Furthermore, it can release the protein in a controlled, prolonged and almost constant manner, in particular avoiding the rapid initial release phenomenon known as "burst release".
[0202] According to the present disclosure, the term "gel" refers to a non-fluid polymer network swollen by a solvent.
[0203] According to the present disclosure, the expression "hydrogel" refers to a viscoelastic material containing at least 60% by weight of water, a physical or chemical gel. A hydrogel is a physical gel. In such a physical gel, the driving force for gel formation is not a chemical reaction forming covalent bonds, but more physical phenomena, such as van der Waals interactions and / or hydrogen bonds and / or electrostatic interactions.
[0204] The hydrogel comprises about 50% to 95% by weight of water, preferably 50% to 80% by weight of water, relative to the total weight of the hydrogel.
[0205] According to the present disclosure, the expression "biodegradable" in relation to a hydrogel formed in situ means that the hydrogel decomposes naturally under physiological conditions, in particular under the action of macrophages. The reactions involved in the biodegradation process may include hydrolysis reactions, i.e. the breaking of covalent bonds by reaction with water. These reactions may be catalyzed by the action of enzymes naturally present at the injection site.
[0206] In one embodiment, when the hydrogel is placed under physiological conditions, typically following subcutaneous injection in a subject, greater than 50% by weight, preferably greater than 80% by weight, preferably greater than 95% by weight of the hydrogel degrades within a period of 10 to 100 days, preferably 20 to 65 days.
[0207] In particular, the hydrogel of the present disclosure can substantially release the protein over a period of 10 to 100 days, preferably 20 to 65 days, from the date of administration of the pharmaceutical formulation of the present invention.
[0208] The long degradation time advantageously enables the time between two injections to be extended. This is particularly advantageous compared to, for example, prior art preparations with hyaluronidase, which must preferably be injected approximately once every two weeks.
[0209] According to the present disclosure, the expression "biocompatible" refers to a hydrogel formed in situ, and refers to a hydrogel having the ability not to degrade in the biological environment it is placed in. In particular, the hydrogel produces little or no inflammatory response even in a long-term biological environment.
[0210] In one embodiment, the hydrogel causes little or no inflammation over a period of 10 to 100 days, preferably 20 to 65 days, from the date of administration of the pharmaceutical formulation of the invention.
[0211] Osmotic pressure
[0212] The pharmaceutical preparation of the present invention preferably has a pH and / or osmotic pressure close to but different from physiological conditions, and particularly lower than physiological conditions. When placed in contact with body fluids under physiological conditions, the pharmaceutical preparation of the present invention forms a gel by changing the pH and / or osmotic pressure by equilibrating with the physiological medium.
[0213] The pharmaceutical preparation preferably has an osmotic pressure of 50 to 600 mOsm / L, preferably 100 to 600 mOsm / L, more preferably 250 to 450 mOsm / L or 50 to 300 mOsm / L, preferably 50 to 250 mOsm / L.
[0214] According to the present disclosure, osmotic pressure (also known as osmolality) refers to the concentration of solutes per unit volume of a solution. Osmotic pressure is similar to molarity, but includes the total number of moles of dissolved substances in a solution. Osmotic pressure is defined as the number of osmols (Osm) of solute per liter (L) of solution (osmol / L or Osm / L). The osmole is calculated to produce the Avogadro particle number (6.0221×10 23 ) and the amount of substance that must be dissolved. For substances that do not dissociate, the molar concentration and osmotic pressure will be the same, while for substances that are ionized, the osmotic pressure will be the molar concentration multiplied by the number of dissociated parts. For example, for sodium chloride, the osmotic pressure will be doubled. The osmotic pressure is the number of osmoles of solute per kilogram of solvent. Physiological osmotic pressures are generally in the range of about 280mOsm / L to about 310mOsm / L, typically about 300mOsm / L.
[0215] The osmotic pressure of the pharmaceutical formulations of the present disclosure is typically measured using an osmometer (e.g., an osmometer from CamlaB). MicroOsmometer MOD200Plus) was used for measurement. Before measurement, 50 μL of distilled water was used to adjust the zero, and then the instrument was calibrated relative to 25 μL of 300mOsm / kg water standard. Samples were measured by taking 25 μL of the same volume and freezing it to -6.0°C. Alternatively, 15 μL of distilled water was used to adjust the zero, and then the instrument was calibrated relative to 15 μL of 300mOsm / kg water standard. Samples were measured by taking 15 μL of the same volume and freezing it to -6.2°C.
[0216] pH
[0217] The pharmaceutical formulation preferably has a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.0.
[0218] The pH of the pharmaceutical formulations of the present disclosure is measured according to methods known to those skilled in the art, for example using a pH meter such as a Mettler Toledo SevenCompact S210 pH meter. According to the present disclosure, the expression "physiological pH" refers to a pH in the range of 6.8 to 7.6, typically about 7.4.
[0219] Proteins in pharmaceutical preparations
[0220] The pharmaceutical formulations of the present disclosure comprise a therapeutically effective amount of a protein or a combination of proteins.
[0221] According to the present disclosure, a "therapeutically effective amount" is the minimum concentration required to achieve a measurable improvement or prevention of any symptom or a specific condition or disease, a measurable enhancement of life expectancy, or an overall improvement in the patient's quality of life. The therapeutically effective amount depends on the specific biologically active molecule and the specific condition or disease to be treated.
[0222] The content of protein or protein combination in the pharmaceutical preparation is usually 1-200 g / l, for example 50-100 g / l of protein or protein combination.
[0223] The therapeutically effective amount of many proteins, such as antibodies as described herein, is well known in the art. The therapeutically effective amount of a protein that has not yet been established or a known protein (such as an antibody) for treating a particular condition that is clinically applied to treat an additional condition can be determined by standard techniques well known to those skilled in the art (such as physicians).
[0224] According to the present disclosure, the term "protein" refers to a polymer of amino acid residues (natural or non-natural) most often linked together by peptide bonds. Proteins include naturally occurring proteins and recombinant proteins. Proteins can be functionally linked (e.g., by chemical coupling, non-covalent association or other) to one or more other molecules, such as small molecules, polymers (e.g., polyethylene glycol) or other proteins. The term "protein" can be a single molecule or can be a multimolecular complex, such as a dimer, trimer or tetramer. They can also include single-chain or multi-chain proteins, such as antibodies. Disulfide bonds are typically present in multi-chain proteins. The term protein is also applicable to amino acid polymers in which one or more amino acid residues are artificial chemical analogs or corresponding natural amino acids.
[0225] In the present disclosure, protein molecular weight can be determined using standard methods known to those skilled in the art, including but not limited to mass spectrometry (e.g., ESI, MALDI, SDS page techniques) or calculated from known amino acid sequence and glycosylation. Proteins can be naturally occurring or non-naturally occurring, synthetic or semi-synthetic. Proteins or combinations of proteins can be particularly derived from human plasma.
[0226] The molecular weight of the protein may be between 10 kDa and 250 kDa, preferably between 20 kDa and 250 kDa, preferably between 100 kDa and 250 kDa, preferably between 120 kDa and 250 kDa, preferably between 150 kDa and 250 kDa.
[0227] In a specific embodiment of the pharmaceutical formulation of the present disclosure, the protein preferably has a molecular weight of 40 kDa to 250 kDa, advantageously 100 kDa to 250 kDa, more advantageously 120 kDa to 250 kDa, even more advantageously 150 kDa to 250 kDa.
[0228] In certain preferred embodiments, the protein or protein combination is selected from the group consisting of antibodies, enzymes, fusion proteins and combinations thereof, in particular antibodies or combinations thereof.
[0229] The pharmaceutical formulations of the present disclosure preferably do not contain recombinant human hyaluronidase PH20 (rHuPH20), and preferably do not contain enzymes capable of degrading hyaluronic acid.
[0230] Antibody
[0231] The protein or combination of proteins is preferably an antibody or a combination of antibodies.
[0232] According to the present disclosure, the term "antibody" refers to an immunoglobulin molecule, i.e., a molecule containing an antigen binding site that immunospecifically binds to an antigen. Therefore, the term "antibody" includes not only whole antibody molecules, but also antibody fragments and variants (including derivatives) of antibodies and antibody fragments.
[0233] The combination of antibodies can be derived from human plasma. In one embodiment, the antibody is derived from the plasma of unselected blood donors. It is known that these antibodies are normal (i.e. non-specific) immunoglobulins that are usually abbreviated as HNI or HNIg. It can be used to provide antibodies to patients suffering from primary immunodeficiency disease (PID), hypogammaglobulinemia, primary immune thrombocytopenia, Guillain-Barre syndrome, Kawasaki disease, multifocal motor neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy or secondary (i.e. acquired) immunodeficiency disease. In another embodiment, the antibody is from the plasma of selected blood donors. This antibody is referred to as "hyperimmune immunoglobulin". They are prepared in a manner similar to normal human immunoglobulin, except that the blood donor has high titer antibodies for specific organisms or antigens in its plasma. Some reagents for hyperimmune globulins including hepatitis B, rabies, tetanus toxin and varicella zoster can be used.
[0234] The antibodies may be monoclonal or polyclonal.
[0235] According to the present disclosure, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., each antibody constituting the population binds to the same epitope, except for possible variants that may occur during the production of the monoclonal antibody, such variants are generally present in small amounts. Contrary to polyclonal antibody preparations that generally include different antibodies for different determinants (epitopes), each monoclonal antibody is directed to a single determinant on the antigen. In addition to their specificity, the advantage of monoclonal antibodies is that they are not contaminated by other immunoglobulins. The term "monoclonal" represents the characteristics of an antibody obtained from a substantially homogeneous antibody population, and should not be construed as requiring the production of antibodies by any particular method. Specific examples of monoclonal antibodies herein include chimeric antibodies, humanized antibodies, and human antibodies.
[0236] According to the present disclosure, a "chimeric" monoclonal antibody is an antibody in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as long as they exhibit the desired biological activity. Chimeric antibodies of interest herein include "primatized" antibodies, which comprise variable domain antigen-binding sequences derived from non-human primates (e.g., baboon, rhesus monkey, or cynomolgus monkey) and human constant region sequences. An example of a chimeric antibody is rituximab.
[0237] According to the present disclosure, the "humanized" form of non-human (e.g., mouse) antibodies is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. To a large extent, humanized antibodies are human immunoglobulins, in which residues from a receptor hypervariable region are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as a mouse, rat, rabbit, or non-human primate with desired specificity, affinity, and ability. In some cases, the framework region (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. In addition, humanized antibodies may include residues not found in receptor antibodies or donor antibodies. These modifications are made to further improve antibody properties. In general, humanized antibodies will include substantially all of at least one, usually two variable domains, wherein all or substantially all of the hypervariable regions correspond to the hypervariable regions of non-human immunoglobulins, and all or substantially all of the FRs are FRs of human immunoglobulin sequences, except for the above-mentioned FR replacements. Humanized antibodies may optionally include at least a portion of an immunoglobulin constant region, typically a constant region of a human immunoglobulin. An example of a humanized antibody is trastuzumab.
[0238] According to the present disclosure, a "full-length antibody" is an antibody comprising an antigen-binding variable region and a light chain constant domain (CL) and heavy chain constant domains CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. Preferably, the full-length antibody has one or more effector functions. Rituximab and trastuzumab are examples of full-length antibodies.
[0239] According to the present disclosure, "antibody fragments" comprise a portion of a full-length antibody that includes the antigen binding region and / or variable region of the full-length antibody. Examples of antibody fragments include Fab, FaB', F(ab')2 and Fv fragments; single domain antibodies. F(ab')2, Fab, Fab' and Fv are antigen binding fragments that can be generated from the variable regions of IgG and IgM. F(ab')2 fragments contain two antigen binding regions connected at the hinge by a disulfide. F(ab')2 fragments are generally free of most, but not all, Fc regions. Fab' fragments can be formed by reducing F(ab')2 fragments. Fab' fragments contain free sulfhydryl groups that can be alkylated or used in conjunction with enzymes, toxins or other proteins of interest. Fab' fragments are derived from F(ab')2; therefore, they can contain a small portion of Fc. FaB is a monovalent fragment generated from IgG and IgM, consisting of VH, CH1 and VL, CL regions connected by intramolecular disulfide bonds. FV fragments refer to the smallest fragments generated from IgG and IgM that contain a complete antigen binding site. The FV fragment has the same binding properties as FaB and similar three-dimensional binding properties. The VH and VL chains of the Fv fragment are bound together by non-covalent interactions. "Single domain antibodies", also known as "nanoantibodies", are monomeric antigen-binding fragments of antibodies that provide various advantages over other antibody fragments as "building blocks" of bsAbs. They exist in camels (called VHH) and cartilaginous fish (called VNAR) as antigen-binding portions of heavy chain antibodies in nature, or can be produced by obtaining or engineering monomeric, stable VH or VL domains from conventional IgG.
[0240] Exemplary antibodies that can be formulated according to the present disclosure include, but are not limited to, Abatacept, Adalimumab, Alemtuzumab, Alirocumab, Amivantamab, Anifrolumab, Atezolizumab, Avelumab, Balstilimab, Basiliximab, Belatacept, Belimumab, Benralizumab, Besilesomab , Bevacizumab, Bezlotoxumab, Bimekizumab, Blinatumomab, Brodalumab, Burosumab, Canakinumab, Carotuxomab, Cemiplimab, Cetuximab, Concizumab, Crizanlizumab, Daratumumab, Denosumab, Dinutuximab Beta), Dostarlimab, Dupilumab, Durvalumab, Eculizumab, Elotuzumab, Epratuzumab, Erenumab, Evolocumab, Fab Ig AntidigitaliqueOvin, Fremanezumab, Galcanezumab, Golimumab, Guselkumab, Ibalizumab, Ig anti-human lymphocytes (Lapine), Ig anti-human thymocytes (Equine), Ig anti-human thymocytes (Lapine), Infliximab, Iph4102, Ipilimumab, Isatuximab, Ixekizumab ab), Lacutamab, Lag525, Lanadelumab, Mcla-128, Mepolizumab, Natalizumab, Naxitamab, Nimotuzumab, Nivolumab, Obinutuzumab, Ocrelizumab, Ofatumumab, Omalizumab, Palivizumab Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Ranibizumab, Reslizumab, Risankizumab, Rituximab, Sarilumab, Secukinumab, Seribantumab, S iltuximab, spartalizumab, tafasitamab, teprotumumab, tildrakizumab, tocilizumab, tralokinumab, trastuzumab, urelumab, ustekinumab, vedolizumab, zaliferimab, and combinations thereof.
[0241] Exemplary combinations of antibodies that can be formulated according to the present disclosure include, but are not limited to, Casirivimab and Imdevimab, a combination of Pertuzumab and Trastuzumab, or a combination of Tixagevimab and Cilgavimab.
[0242] An antibody may be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecules to increase half-life or stability or otherwise improve the antibody.
[0243] For example, the antibody can be linked to one of a variety of non-protein polymers, such as polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylene, or a copolymer of polyethylene glycol and polypropylene glycol. The antibody can be functionally linked to poly(ethylene glycol), such as the antibody is Certolizumab Pegol. The antibody can be functionally linked to a chelator such as DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclododecane-1-pentanedioic acid-4,7-diacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid), DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), NOTAM (1,4,7-tetraazacyclododecane-1,4,7-triazacyclononane), DOTP (1,4,7,10-tetraazacyclododecane-1,4,7-triazacyclododecane), Heterocyclododecane-1,4,7,10-tetrakis(methylenephosphonate), NOTP (1,4,7-tetrakis(methylenephosphonate)-1,4,7-triazacyclotetradecane), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetraacetic acid), TETAM (1,4,8,11-tetraazacyclotetradecane-N,N',N",N""-tetrakis(carbamoylmethyl)), DTPA (diethyltriaminepentaacetic acid), DFO (deferoxamine), Bz-DFO and bispitine ([3,7]-diazabicyclo[3.3.1]nonane), preferably functionally linked to a chelating agent selected from DOTAGA, DFO, Bz-DFO, DOTAM, DTPA and bispitine.
[0244] The antibody can also be functionally linked to a cytotoxic agent such as calicheamicin, monomethyl auristatin F (MMAF, also known as mafodotin), monoethyl auristatin E (MMAE, also known as vedotin), Emtamine (DM1), a derivative of exotecan (Dxd), N-acetyl-γ calicheamicin to form an antibody-drug conjugate. Exemplary antibody-drug conjugates (ADCs) that can be formulated according to the present disclosure include, but are not limited to, Mafodotine, Vedotin, Mafodotine, Vedotin, Gemtuzumab Ozogamicine, Ozogamicine, Pasudotox, Govitecan, Trastuzumab Deruxtecan, and Trastuzumab Emtansine.
[0245] Antibodies can be functionally linked to one or more antibodies or antibody fragments to produce bispecific or multispecific molecules. Exemplary bispecific antibodies that can be formulated according to the present disclosure include, but are not limited to, Grofituzumab, KN046, IBI318, IBI318, Imisecuzumab, Icoretuzumab, Tepolizumab, Tebentafusp, Terituzumab, Faresimonab, Evantuzumab, Motuzumab, Zenidatuzumab, Futuzumab, APVO436, Zetuzumab, TNB383B, and combinations thereof. In one embodiment, the formulated bispecific antibody is Icoretuzumab.
[0246] In one embodiment, the protein or protein combination is an antibody or antibody combination that binds to an antigen selected from HER2 and CD20. CD20 antibodies can be used to treat B cell malignancies (such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia) or autoimmune diseases (such as rheumatoid arthritis and vasculitis); HER2 antibodies can be used for cancer treatment (such as breast cancer or gastric cancer). The phrases "antibodies that bind to antigens", "antibodies that recognize antigens" and "antibodies that are specific for antigens" have the same meaning and are used equally herein.
[0247] In one embodiment, the formulated antibody binds HER2. In a preferred embodiment, the formulated antibody is trastuzumab.
[0248] In one embodiment, the formulated antibody binds CD20. In a preferred embodiment, the formulated antibody is rituximab.
[0249] In one embodiment, the formulated antibody binds HER2. In a preferred embodiment, the formulated antibody is Pertuzumab.
[0250] In one embodiment, the formulated antibody binds CD38. In a preferred embodiment, the formulated antibody is daratumumab.
[0251] In one embodiment, the formulated antibody combination is a combination of antibodies that bind to two different epitopes of HER2. In a preferred embodiment, it includes a combination of trastuzumab and pertuzumab.
[0252] excipient
[0253] The pharmaceutical formulations of the present disclosure may further comprise one or more pharmaceutically acceptable excipients selected from solvents, stabilizers, surfactants, buffers, antimicrobial preservatives, protectants, antioxidants, chelating agents, and fillers.
[0254] According to the present disclosure, a "solvent" is any pharmaceutically acceptable (i.e., safe and non-toxic for administration to a human or another mammal) and useful ingredient for preparing a liquid formulation, such as an aqueous formulation. Exemplary solvents include water, such as sterile water for injection (WFI) or bacteriostatic water for injection (BWFI), a pH buffered solution (e.g., phosphate-buffered saline), a sterile saline solution, Ringer's solution, or a dextrose solution, and combinations thereof. Preferably, the solvent is sterile water for injection or bacteriostatic water for injection (BWFI) of the present disclosure.
[0255] According to the present disclosure, a stabilizer is a compound that increases protein stability, in particular against unfolding and aggregation. Preferably, the stabilizer is approved by the authorities as a suitable additive or excipient in pharmaceutical formulations.
[0256] The stabilizer can be a sugar. The term "sugar" herein includes the general composition (CH2O) n and derivatives thereof, including monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, etc. Examples of sugars herein include glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerol, dextran, erythritol, glycerol, arabitol, xylitol, sorbitol, mannitol, melibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, isomaltulose, etc.
[0257] Preferably, the formulation comprises a non-reducing disaccharide as a stabilizer, for example a sugar selected from trehalose (eg in the form of α,α-trehalose dihydrate) and sucrose.
[0258] The concentration of the stabilizer in the pharmaceutical formulation of the present disclosure is preferably 1 to 500 mM, 15 to 250 mM, or 150 to 250 mM, or about 210 mM.
[0259] According to the present disclosure, "surfactant" refers to a surface-active agent. Surfactants are usually added to protein formulations to reduce the exposure of hydrophobic regions, thereby reducing protein-protein interactions and interface-induced aggregation, which is also prevented by competing for adsorption sites.
[0260] Examples of surfactants herein include polysorbates (e.g., polysorbate 20 and polysorbate 80); poloxamers (e.g., poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauryl amide The pharmaceutically acceptable surfactants include propyl-, cocoamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmitoylaminopropyl- or isostearamidopropyl-betaine (e.g., lauroylamidopropyl); myristamidopropyl-, palmitoylaminopropyl- or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or sodium methyl oleyl-taurate; polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.). Other examples of pharmaceutically acceptable surfactants include polyoxyethylene-sorbitan fatty acid esters (Tween), polyethylene-polypropylene glycol, polyoxyethylene stearate, polyoxyethylene alkyl ethers, such as polyoxyethylene monolauryl ether, alkylphenol polyoxyethylene ether (Triton-X), polyoxyethylene-polyoxypropylene copolymers (Poloxamer, Pluronic) and sodium dodecyl sulfate (SDS). The most suitable polyoxyethylene sorbitan-fatty acid ester is polysorbate 20 (marketed under the trademark Tween 20 TM ) and polysorbate 80 (sold under the trademark Tween 80 TM Sale).
[0261] The most suitable polyethylene-polypropylene copolymer is sold under the trade name F68 or Poloxamer 188 TM The most suitable polyoxyethylene alkyl ethers are sold under the trademark Brij TM The most suitable alkylphenol-polyoxyethylene ether is sold under the trade name Triton-X.
[0262] The surfactant is preferably a nonionic surfactant, preferably a polysorbate, for example selected from polysorbate 20, polysorbate 80 and polyethylene polypropylene copolymer.
[0263] The concentration of the surfactant in the pharmaceutical formulation of the present disclosure is preferably 0.01% to 0.1% (w / v), or 0.01% to 0.08% (w / v), or 0.025% to 0.075% (w / v).
[0264] According to the present disclosure, the term "buffer" refers to an agent that provides a solution containing it with resistance to pH changes through the action of its acid / base conjugate components. Examples of buffers that control pH within this range include acetate, succinate, gluconate, histidine, citrate, glycylglycine and other organic acid buffers.
[0265] A suitable buffer in the present disclosure is a histidine buffer.
[0266] A "histidine buffer" is a buffer comprising the amino acid histidine. Examples of histidine buffers include histidine chloride (eg, L-histidine hydrochloride monohydrate), histidine acetate, histidine phosphate, histidine sulfate.
[0267] "Anticorrosive agent" is a compound that can be added to the preparation herein to reduce the pollution and / or effect of bacteria, fungi or another infectious agent. The addition of anticorrosive agent can, for example, promote the production of multi-purpose (multiple dose) preparations. Examples of potential anticorrosive agents include dodecyl dimethyl benzyl ammonium chloride, hexamethyl ammonium chloride, benzalkonium chloride (wherein the alkyl group is a mixture of long-chain dimethyl benzyl ammonium chloride) and benzethonium chloride. Other types of anticorrosive agents include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parahydroxybenzoates such as methyl parahydroxybenzoate or propyl parahydroxybenzoate, catechol, resorcinol, cyclohexanol, 3-pentanol and meta-cresol.
[0268] As generally used herein, a "protectant" is a substance that, when combined with a protein, significantly reduces the chemical and / or physical instability of the protein upon lyophilization and / or subsequent refrigerated storage.
[0269] Exemplary protective agents include sugars and their corresponding sugar alcohols, such as sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol and mannitol; amino acids, such as arginine or histidine; lyotropic salts, such as magnesium sulfate; polyols, such as propylene glycol, glycerol, poly(ethylene glycol) or poly(propylene glycol); and combinations thereof. Other examples of protective agents include gelatin, dextrin, modified starch and carboxymethyl cellulose. Preferred sugar alcohols are those compounds obtained by reducing monosaccharides and disaccharides, such as lactose, trehalose, maltose, lactulose and maltulose. Other examples of sugar alcohols are glucitol, maltitol, lactitol and isomaltulose.
[0270] The protective agent may be added to the pre-lyophilized formulation in a "lyophilization-protective amount." This means that after lyophilization of the protein in the presence of the lyophilization-protective amount of the protective agent, the protein substantially retains its physical and chemical stability and integrity.
[0271] "Antioxidants" as generally used herein are pharmaceutically acceptable excipients that are generally used to limit oxidation reactions and maintain the stability and safety of proteins. Examples of antioxidants are ascorbic acid, sodium pyrosulfite, histamine, methionine, ascorbic acid, glutathione, vitamin E, polyethyleneimine.
[0272] The antioxidant is preferably methionine, especially L-methionine.
[0273] The concentration of the antioxidant in the pharmaceutical preparation of the present disclosure is preferably 5 to 25 mM, more preferably 5 to 15 mM.
[0274] In the case of excipients, "chelating agents" as generally used herein are pharmaceutically acceptable excipients that are generally used to maintain protein stability.
[0275] Examples of chelating agents include disodium edetate, diethylenetriaminepentaacetic acid, citric acid, hexaphosphate, thioglycolic acid, zinc.
[0276] As generally used herein, "fillers" are pharmaceutically acceptable excipients that are generally used to add substances to a lyophilized mixture and contribute to the physical structure of the lyophilized cake (e.g., promoting the production of a substantially uniform lyophilized cake that maintains an open-pore structure). Exemplary fillers include mannitol, glycine, lactose, modified starches, poly(ethylene glycol), and sorbitol.
[0277] Specific drug preparations
[0278] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0279] a protein or a combination of proteins, preferably an antibody or a combination of antibodies as defined herein, in particular trastuzumab, rituximab, pertuzumab, daratumumab, or a combination of trastuzumab and pertuzumab,
[0280] - a mixture of polysaccharides as defined herein,
[0281] - and preferably at least one of the following
[0282] o A buffer, stabilizer or antioxidant as defined herein.
[0283] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0284] 1 g / l to 200 g / l, preferably 100 to 150 g / l of an antibody or a combination of antibodies, in particular trastuzumab, rituximab, pertuzumab, daratumumab, or a combination of trastuzumab and pertuzumab,
[0285] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0286] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0287] - and preferably at least one of the following:
[0288] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0289] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0290] o 5 to 25 mM of an antioxidant, preferably methionine.
[0291] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0292] - 1 g / l to 200 g / l, preferably 100 g / l to 150 g / l of trastuzumab,
[0293] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0294] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0295] - and preferably at least one of the following:
[0296] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0297] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0298] o 5 to 25 mM of an antioxidant, preferably methionine.
[0299] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0300] - 1 g / l to 200 g / l, for example 5 to 20 g / l, preferably 100 to 150 g / l of rituximab,
[0301] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0302] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0303] - and preferably at least one of the following:
[0304] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0305] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0306] o 5 to 25 mM of an antioxidant, preferably methionine.
[0307] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0308] 1 g / l to 200 g / l, such as 30 to 50 g / l or about 40 g / l, preferably 100 to 150 g / l of trastuzumab,
[0309] 1 g / l to 200 g / l, for example 50 g / l to 100 g / l or about 80 g / l, preferably 100 g / l to 150 g / l of Pertuzumab,
[0310] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0311] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0312] - and preferably at least one of the following:
[0313] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0314] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0315] o 5 to 25 mM of an antioxidant, preferably methionine.
[0316] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0317] - 1 g / l to 200 g / l, for example 50 g / l to 100 g / l, preferably 100 g / l to 150 g / l of Pertuzumab,
[0318] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0319] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0320] - and preferably at least one of the following:
[0321] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0322] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0323] o 5 to 25 mM of an antioxidant, preferably methionine.
[0324] In one embodiment, the pharmaceutical formulation of the present disclosure preferably comprises:
[0325] 1 g / l to 200 g / l, for example 50 g / l to 100 g / l, preferably 100 g / l to 150 g / l of daratumumab,
[0326] - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A,
[0327] - 10 to 200 g / l, preferably 20 to 100 g / l of statistical polysaccharide B,
[0328] - and preferably at least one of the following:
[0329] o 1 to 100 mM buffer, preferably a histidine buffer, more preferably a histidine chloride buffer such as L-histidine hydrochloride monohydrate, to provide a pH of 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.00,
[0330] o 1 to 500 mM of a stabilizer, preferably trehalose, such as α,α-trehalose dihydrate, or
[0331] o 5 to 25 mM of an antioxidant, preferably methionine.
[0332] Stability over time
[0333] The pharmaceutical preparation of the present disclosure can be stored for a long period of time, usually for at least 6 months, preferably for 6 months to 1 year.
[0334] Ready to use
[0335] In one embodiment, the pharmaceutical formulation of the present disclosure is in the form of a ready-to-use (ie, ready-to-administer) injectable formulation containing a polysaccharide mixture as defined in the present disclosure, a protein or a combination of proteins and one or more pharmaceutically acceptable excipients.
[0336] In this embodiment, the pharmaceutical formulation may be provided, for example, in a pre-filled syringe.
[0337] Preparation method
[0338] In a second aspect, the present disclosure relates to a method for preparing a pharmaceutical formulation as defined in the first aspect of the present disclosure, which comprises at least the step of mixing a polysaccharide mixture, a protein or a protein combination as defined in the first aspect of the present disclosure and one or more pharmaceutical excipients.
[0339] In an embodiment, the method comprises the following steps:
[0340] a) providing a solution containing a polysaccharide mixture as defined in the first aspect of the present disclosure,
[0341] b) providing a solution containing a protein or a combination of proteins as defined in the first aspect of the present disclosure,
[0342] c) mixing the solution of step a) and the solution of step b) to obtain a homogeneous solution,
[0343] d) optionally, adjusting the osmotic pressure of the solution obtained in step c) to provide an osmotic pressure of 50 to 300 mOsm / L, preferably 50 to 250 mOsm / L,
[0344] e) Optionally, the pH of the solution obtained in step c) is adjusted to 5.0 to 6.5, preferably 5.0 to 6.4, more preferably 5.5 to 6.0.
[0345] The solutions of step a) and step b) are preferably aqueous solutions.
[0346] The solution of step b) may be prepared by dissolving the protein in powdered form (eg lyophilized form), typically by mixing the powder with a solvent (particularly a solvent suitable for injection) to form a solution containing the protein or combination of proteins.
[0347] Step c) can be performed by centrifugation. For example, centrifugation can be performed at 2000 to 8000 rpm for 5 to 30 minutes, preferably at about 5000 rpm for 10 minutes, or at 50 to 200 rpm for 1 to 4 hours, preferably at about 100 rpm for 1 hour. Alternatively, centrifugation can be performed after step c) to remove bubbles from the solution obtained in step c).
[0348] In one embodiment, step c) can be performed by a static mixer. In this embodiment, the solution of step a) is contained in a first container and the solution of step b) is contained in a second container, the containers are connected to a static mixer to provide a system for mixing the solution of step a) and the solution of step b) by injecting the contents of one solution into the other solution and vice versa. This injection can be repeated 100 to 500 times, typically 100 to 300 times.
[0349] Step c) is preferably carried out in a static mixer.
[0350] In one embodiment, step c) can be performed by directly mixing the solution of step a) and the solution of step b) in a reactor by means of a static mixer.
[0351] The optional osmotic pressure adjustment of step d) can be performed by suitable dialysis of the solution obtained in step c), for example against water or a solution containing a salt such as sodium chloride, optionally maintaining the pH by adding a basic solution.
[0352] The optional pH adjustment of step e) can be carried out by appropriate addition of a base or an acid, preferably a base such as sodium hydroxide.
[0353] Steps d) and e) can be performed in any order, i.e. step d) before step e), or step e) before step d), or can be performed simultaneously. For example, the osmotic pressure can be adjusted by dialysis while maintaining the pH, or vice versa.
[0354] Part of the kit
[0355] A third aspect of the present disclosure relates to a kit comprising:
[0356] - at least one first container containing chitosan A and statistical polysaccharide B, ie a polysaccharide mixture as defined in the first aspect of the present disclosure,
[0357] - at least one second container containing a protein or a combination of proteins as defined in the first aspect of the present disclosure.
[0358] The kit is used for preparing the pharmaceutical preparation according to the present disclosure, in particular the ready-to-use injectable preparation according to the present disclosure.
[0359] In one embodiment, the polysaccharide mixture of the first container is in the form of a powder or a liquid solution.
[0360] In one embodiment, the protein or combination of proteins of the second container is in the form of a powder or a liquid solution.
[0361] In one embodiment, the polysaccharide mixture of the first container and the protein or protein combination of the second container are in the form of a powder or a liquid solution.
[0362] In one embodiment, the first and second containers may be connected to a static mixer that provides a mechanism for mixing the polysaccharide mixture and the protein or protein combination.For example, the first and second connectors may include Luer lock adapters and be connected via Luer lock connectors.
[0363] The first and / or second container is preferably a syringe, more preferably a ready-to-use syringe. In one embodiment, the first and second containers are Luer lock vials or syringes connected by a Luer lock connector.
[0364] The kits of the present disclosure allow for the preparation of pharmaceutical compositions from sterile commercial proteins from any source, thereby creating great versatility.
[0365] Furthermore, the kits of the present disclosure allow for the preparation of the formulation shortly prior to injection.
[0366] If the kit comprises excipients other than solvents and buffers as stabilizers, these are preferably in the second container.
[0367] Application
[0368] The pharmaceutical formulations of the present disclosure are preferably suitable for injection, preferably subcutaneous injection.
[0369] As generally used herein, "injectability" or "syringability" refers to the injectable property of a drug formulation through a syringe equipped with an 18-32 gauge needle, preferably a 20-27 gauge needle.
[0370] According to the present invention, "subcutaneous injection" refers to injection administration into the subcutaneous tissue (the skin layer just below the dermis and epidermis), collectively referred to as the skin. Subcutaneous administration can be abbreviated as SC, SQ, sub-cu, sub-Q, SubQ or subcut.
[0371] Subcutaneous injections may be given in any area suitable for subcutaneous injection, such as the thigh, abdomen, especially at the umbilicus, upper arm, especially the back or side of the lower upper arm, back, lower waist and buttocks, especially the upper outer area of the buttocks.
[0372] Multiple subcutaneous injections can be given simultaneously in different areas suitable for subcutaneous injection.
[0373] Subcutaneous injection volumes may range from 1 to 20 ml, preferably from 2 to 15 ml.
[0374] As shown in the experimental part of this application, the pharmaceutical composition injection volume does not interfere with the degradation kinetics of the hydrogel formed after injection. In addition, it is also shown that the scaffold of the hydrogel formed after injection and thus the release of the captured protein can be adjusted according to, for example, the weight ratio of chitosan A / polysaccharide B.
[0375] In one embodiment, the subcutaneous injection volume is 1 to 5 ml, preferably 1 to 3 ml, preferably about 2 ml. In this embodiment, the subcutaneous injection is preferably performed in the subcutaneous tissue of the thigh, upper arm, back and lower back.
[0376] In one embodiment, the subcutaneous injection volume is 5 to 20 ml, preferably 5 to 10 ml or 10 to 20 ml, more preferably about 15 ml. In this embodiment, the subcutaneous injection is preferably performed in the subcutaneous tissue of the abdomen.
[0377] The pharmaceutical preparations may also be administered by intraperitoneal, intraarticular, intrathecal or intraocular injection.
[0378] According to the present disclosure, "intraocular injection" (also called intravitreal injection) refers to a route of administration via injection inside the eye via the vitreous body, the gel-like substance that fills the eye.
[0379] According to the present disclosure, "intra-articular injection" means a route of administration via injection into a joint. Intra-articular injection can be used for chemotherapy as well as for the treatment of arthritis.
[0380] According to the present disclosure, "intrathecal administration" means an administration route via injection into the spinal canal or subarachnoid space so that it reaches the cerebrospinal fluid (CSF). Intrathecal administration can be a useful chemotherapy.
[0381] The pharmaceutical preparations may also be administered by intratumoral injection.
[0382] According to the present invention, "intratumoral injection" refers to direct injection into a tumor. Intratumoral injection may be considered for any tumor in which the primary lesion or its metastasis can be reached via direct percutaneous (i.e., puncture of the skin) injection or via specific procedures such as colonoscopy, cystoscopy, bronchoscopy, thoracoscopy, colonoscopy or even surgery.
[0383] Injections can be performed with 18-32 gauge needles, preferably 20-27 gauge needles. The formulations can be administered using a small gauge needle, such as 20-30 gauge, typically 27, 28, 29 or 30 gauge.
[0384] In one embodiment, the pharmaceutical formulation does not cause significant inflammation when administered no more than twice a day, once a day, twice a week, once a week, once every two weeks, or monthly. The pharmaceutical formulation of the present disclosure is preferably administered once every two weeks and does not cause significant inflammation at the injection site.
[0385] In one embodiment, when administered by subcutaneous injection, the pharmaceutical formulation exhibits increased bioavailability compared to a formulation comprising the same protein."Bioavailability" refers to the extent and rate at which a protein, such as an antibody, reaches the circulation or site of action. One method of measuring bioavailability is by comparing the "area under the curve" (AUC) in a graph of plasma concentration as a function of time.
[0386] AUC can be calculated, for example, using the linear trapezoidal rule. According to the present disclosure, "AUC0" refers to the area under the plasma concentration curve from time zero to the time when the plasma concentration returns to the baseline level. According to the present disclosure, "AUC 0-t ” refers to the area under the plasma concentration curve from time zero to time t later, e.g., to the time when baseline is reached. Time is usually measured in days, but hours may also be used depending on the context. For example, AUC may be increased by 10%, 20%, 30%, 40% or 50% or more compared to an otherwise identical formulation not containing the viscosity-reducing water-soluble organic dye and administered in the same manner.
[0387] According to the present disclosure, “t max ” refers to the time after administration when the plasma concentration reaches the maximum value.
[0388] According to this disclosure, “C max ” refers to the maximum plasma concentration after administration of a dose and before administration of the subsequent dose.
[0389] According to this disclosure, “C min ” refers to the minimum plasma concentration after administration of a dose and before administration of the subsequent dose.
[0390] In one embodiment, an advantageous feature of the pharmaceutical formulations of the present disclosure is that the t max , after injection, preferably SC injection max The preparation is generally a drug containing recombinant human hyaluronidase PH20 (rHuPH20) or more generally an enzyme capable of degrading hyaluronic acid, and this increase is greater than or equal to 1.5 times, preferably greater than or equal to 3 times.
[0391] Without wishing to be bound by any theory, the inventors believe that the T max Increased confirmation of trastuzumab release compared to ROCHE SC preparation is slow.
[0392] Compared with the pharmaceutical formulations without polysaccharide mixture, the pharmaceutical formulations of the present disclosure can allow greater dosage flexibility and reduced dosage frequency. For example, by increasing the dose administered per injection multiple times, the dosage frequency can be reduced from once every 2 weeks to once every 6 weeks in some embodiments.
[0393] Therapeutic Uses
[0394] In a fourth aspect, the present disclosure relates to the pharmaceutical formulation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure, for use as a medicament, preferably for the treatment of cancer.
[0395] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma (including medulloblastoma and retinoblastoma), sarcoma (including liposarcoma and synovial cell sarcoma), neuroendocrine tumors (including carcinoid tumors, gastrinomas, and islet cell carcinomas), mesothelioma, schwannoma (including acoustic neuroma), meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies (including Warren B. Macroglobulinemia), multiple myeloma, or myeloid neoplasms. More specific examples of such cancers include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer), non-small cell lung cancer, lung adenocarcinoma and lung squamous carcinoma, peritoneal cancer, hepatocellular carcinoma, stomach or gastric cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, testicular cancer, esophageal cancer, biliary tract tumors, and head and neck cancer.
[0396] The pharmaceutical preparation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure can also be used to treat non-malignant diseases, in particular non-malignant diseases selected from the following: autoimmune diseases (e.g., psoriasis); endometriosis; scleroderma; restenosis; polyps such as colon polyps, nasal polyps or gastrointestinal polyps; fibroadenomas; respiratory diseases; cholecystitis; neurofibromatosis; polycystic kidney disease; inflammatory diseases; skin diseases, including psoriasis and dermatitis; vascular diseases; disorders involving abnormal proliferation of vascular epithelial cells; gastrointestinal ulcers; menstrual disorders, secretory adenomas or protein loss syndromes; kidney disorders; angiogenic disorders ocular diseases, such as age-related macular degeneration, presumed ocular histoplasmosis syndrome, retinal neovascularization due to proliferative diabetic retinopathy, retinal angiogenesis, diabetic retinopathy, or age-related macular degeneration; bone-related conditions, such as osteoarthritis, rickets, and osteoporosis; injury following a cerebral ischemic event; fibrotic or edematous diseases, such as cirrhosis of the liver, pulmonary fibrosis, sarcoidosis, thyroiditis, systemic hyperviscosity syndrome, hereditary hemorrhagic telangiectasia, chronic obstructive pulmonary disease, or edema following burns, trauma, radiation, stroke, hypoxia, or ischemia; skin hypersensitivity reactions; diabetic retinopathy and diabetic nephropathy; Guillain-Barré syndrome; graft-versus-host disease or transplant rejection; Paget's disease; bone or joint inflammation; photoaging (e.g., caused by UV radiation of human skin); benign prostatic hypertrophy; certain microbial infections, including microbial pathogens selected from adenovirus, hantavirus, Borrelia burgdorferi, Yersinia spp., and Borrelia pertussis; thrombosis caused by platelet aggregation; reproductive disorders, such as endometriosis, ovarian hyperstimulation syndrome, preeclampsia, dysfunctional uterine bleeding, or menorrhagia; synovitis; atherosclerosis; acute and chronic renal failure The following are some of the diseases that may be considered to ...Exemplary non-malignant indications for treatment herein include psoriasis, endometriosis, scleroderma, vascular disease (e.g., restenosis, atherosclerosis, coronary artery disease, or hypertension), colon polyps, fibroadenomas, or respiratory diseases (e.g., asthma, chronic bronchitis, bronchiectasis, or cystic fibrosis), inflammatory bowel disease (IBD), primary immunodeficiency disease (PID), hypogammaglobulinemia, primary immune thrombocytopenia, Guillain-Barré syndrome, Kawasaki disease, multifocal motor neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy.
[0397] In the present disclosure, the term "treatment" encompasses curative treatment or prophylactic treatment. The term "curative treatment" refers to treatment intended to cure a disease or to ameliorate symptoms associated with a disease. The term "prophylactic treatment" refers to treatment intended to prevent a disease or to ameliorate symptoms associated with a disease.
[0398] In one embodiment, the pharmaceutical formulation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure comprises an antibody or a combination of antibodies.
[0399] In one embodiment, the pharmaceutical preparation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure comprises an antibody or a combination of antibodies that binds to an antigen selected from HER2, such as trastuzumab, pertuzumab or a combination thereof, and is used to treat breast cancer, gastric cancer, B-cell malignancies (such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia), or autoimmune diseases (such as rheumatoid arthritis and vasculitis).
[0400] In one embodiment, the pharmaceutical preparation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure comprises an antibody or a combination of antibodies that binds to an antigen selected from a CD20 antibody such as rituximab and is used to treat rheumatoid arthritis, non-Hodgkin's lymphoma (NHL), leukemia such as chronic lymphocytic leukemia, granulomatosis with polyangiitis (Gpa or Wegener's disease), microscopic polyangiitis (Mpa) or pemphigus vulgaris.
[0401] In one embodiment, the pharmaceutical formulation of the first aspect of the present disclosure or the kit of the second aspect of the present disclosure comprises an antibody or a combination of antibodies that binds to an antigen selected from a CD38 antibody such as daratumumab and is used to treat multiple myeloma or a myeloid tumor.
[0402] In a fifth aspect, the present disclosure relates to a method of treating cancer or a non-malignant disease as defined in the fourth aspect of the present disclosure in a subject in need thereof, the method comprising subcutaneously administering a therapeutically effective amount of a pharmaceutical formulation of the present disclosure in the subject.
[0403] In a sixth aspect, the present disclosure relates to use of a pharmaceutical formulation as disclosed herein in the preparation of a medicament for treating cancer or a non-malignant disease as defined in the fourth aspect of the present disclosure.
[0404] According to the present disclosure, the singular forms "a," "an," and "the" include singular and plural referents unless the context clearly dictates otherwise.
[0405] According to the present disclosure, when the term "about" or "approximately" herein refers to a measurable value such as a parameter, amount, duration, etc., it is meant to cover variations of + / - 5% or less, more preferably + / - 2%, and more preferably + / - 1% or less of the specified value, where such variations are suitable for implementation in the disclosed invention. Example
[0406] The present disclosure is further illustrated by the following examples.
[0407] The materials used in the examples are as follows:
[0408] Non-functionalized precursor chitosan (Chitosan A)
[0409] The synthesis of MEX-CD2-I-tmb involves a non-functionalized precursor chitosan (chitosan A) of medical grade and animal origin. The weight-average molar mass and number-average molar mass (Mw = 2,583.105 g / mol, Mn = 1,323.105 g / mol, respectively) were determined by size exclusion chromatography combined with refractive index and multi-angle laser scattering measurements (Schatz et al. Biomacromolecules, 2003; 4 (3): 641-8). The degree of acetylation (proportion of N-acetyl-D-glucosamine units) of this crude chitosan (chitosan A) was determined by 1H NMR spectroscopy using the Hirai method (Hirai et al., Polymer Bulletin, 26, 87-94. 1991) and was estimated to be 6 ± 0.5%.
[0410] Polysaccharide MEX-CD2 (Polysaccharide B)
[0411] This synthesis of MEX-CD2-I-tmb also concerns the polysaccharide MEX-CD2 (polysaccharide B) obtained after chemical modification of chitosan A with DOTA-GA anhydride, the synthesis of which is described in the previous patent application FR 2110474. Briefly, 60 g of chitosan are introduced into a 10 L reactor together with 4 L of ultrapure water and 50 mL of acetic acid, and the mixture is then placed under mechanical stirring at 500 rpm. After complete dissolution of the chitosan (3 h), 4 L of 1,2-propylene glycol are added to the medium and the mixture is kept stirring until homogenized (2 h). 120 g of DOTA-GA anhydride are then added and the mixture is kept stirring overnight. The mixture is then heated to 40 ℃ and 10 ℃ with a temperature of 100 ℃. Slice PESU cassette (polyethersulfone membrane; cut-off: 100 kDa; filtration area: 0.1 m 2 )of The synthesized product was purified by tangential flow filtration using an Advanced device according to a diafiltration-concentration model using 200 L of a 0.1 M acetic acid solution and then 200 L of a 5 mM acetic acid solution. The degree of acetylation of polysaccharide B was the same as that of the starting chitosan A, and the degree of substitution of polysaccharide B (the proportion of N-DOTAGA-D-glucosamine units) was determined by the copper chelation method (Natuzzi et al., Nature Scientific Reports, 2021, 11, 19948) and was estimated to be 15±0.5%.
[0412] Trastuzumab
[0413] The synthesis of MEX-CD2-I-tmb involves the antibody trastuzumab. Trastuzumab was obtained from a commercially available concentrate for infusion. Powder. One vial contains 420 mg of trastuzumab and excipients, namely L-histidine hydrochloride monohydrate, L-histidine, sucrose and polysorbate 20 (E432).
[0414] The in vivo experiments involved a 50 μg / ml hyaluronidase containing trastuzumab and recombinant human hyaluronidase (rHuPH20) as key excipients. SC preparation. The SC formulation is in the form of a 600 mg / 5 mL single-dose vial. It is a ready-to-use solution for injection that does not require dilution.
[0415] Example 1: Preparation of the formulation MEX-CD2-I-tmb (also called MEX-CD2-I-HER2) according to the invention according to method 1
[0416] According to method (1), the preparation of MEX-CD2-I-tmb is carried out from a viscous solution of a composition called MEX-CD2-I solution in the ratio α / β%, where α is the mass concentration (w / v) of chitosan A in the formulation under consideration and β is the mass concentration (w / v) of polysaccharide B in the formulation under consideration.
[0417] Briefly, 3.0 g of polysaccharide B (MEX-CD2) and 1.5 g of chitosan A were dispersed in 28.93 mL of milli-Q water and 1.07 mL of ultrapure acetic acid was added in a 50 mL reactor under mechanical stirring at 50 rpm. The mixture was placed under stirring for 24 hours until the medium was completely dissolved and homogenized.
[0418] The obtained solution was recovered and introduced into a suitable fluid dispenser, and then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution containing the composition. A MEX-CD2-I solution was obtained.
[0419] In this method (1), 1.5 mL of this 5 / 10% MEX-CD2-I solution was mixed in a reactor with 1.5 mL of 420 mg of 1% MEX-CD2-I previously reconstituted to 250 g / L in 1.68 mL of milli-Q. The solution (a commercially available trastuzumab solution formulated with an excipient containing histamine buffer and a surfactant) was mixed thoroughly.
[0420] The mixture was centrifuged at 5000 rpm for 10 minutes and then mixed again to homogenize the solution. This step was repeated three times until a uniform opaque white viscous solution was obtained.
[0421] The mixture is then introduced into Float-A- The dialysis solution was then changed to 8 g / L sodium chloride solution, in which the pH was still maintained at 6.5 by adding 0.1 mol / L NaOH solution, and the dialysis was continued for 48 hours. At the end of the dialysis, the dialysis tube was weighed again to estimate the dilution factor (C 曲妥珠单抗 =88g / L; C MEX-CD2 =52g / L).
[0422] Mettler Toledo SevenCompact S210 pH meter and Camlab A MicroMOD200 Plus osmometer measured the pH and osmolality of the mixture (pH = 5.6; osmolality = 268 mOsm / L).
[0423] The injection test was performed using different needle diameters and a 1 mL syringe to qualitatively assess the injectability of the solution. The ability to inject through the needle was given a score of 1 to 10, with solutions that could not or were very difficult to inject being given a score of 1; solutions that were very easy to inject being given a score of 10.
[0424] In the buffered hemodialysis solution (Hemosol B0, containing 1.75mmol / L Ca 2+ , 0.5mmol / L Mg 2 + , 140mmol / L Cl - , 3mmol / L lactate and 32mmol / L HCO 3- The gelation test of the solution was carried out in a hemodialysis / hemofiltration solution (hemodialysis / hemofiltration solution) to qualitatively evaluate the strength of the formed hydrogel. A score of 1 to 10 was given for the resistance of the gel in the medium, with a very resistant gel being given a score of 10. The results are shown in Table 1 and examples of the resulting hydrogels are shown in Figure 1 middle.
[0425]
[0426]
[0427] Table 1 - Qualitative estimation of the injectability and gelation ability of MEX-CD2-I-tmb solutions synthesized according to method 1 and with different needle diameters
[0428] These results indicate that the synthesized solution is easy to inject by the operator and involves a wide range of needles commonly used in the medical field for subcutaneous injection of active substances or various pharmaceutical products. In addition, in situ gelation of the solution was observed after injection in a medium under physiological conditions (pH=7.4 and osmotic pressure=300mOsm / L).
[0429] Example 2: Preparation of the formulation MEX-CD2-I-tmb (also called MEX-CD2-I-HER2) according to the invention according to method 2
[0430] According to method (2), the preparation of MEX-CD2-I-tmb is carried out from a viscous solution of a composition called MEX-CD2-I solution in the ratio α / β%, where α is the mass concentration (w / w) of chitosan A in the formulation under consideration and β is the mass concentration (w / w) of polysaccharide B in the formulation under consideration.
[0431] Briefly, 1.33 g of polysaccharide B (MEX-CD2) and 0.67 g of chitosan A were dispersed in 19.87 mL of milli-Q water and 150 μL of ultrapure acetic acid was added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture was stirred for 2 hours until the medium was completely dissolved and homogenized. The resulting solution was recovered and introduced into a suitable fluid dispenser and then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution containing the composition. The pH was measured using a Mettler Toledo SevenCompact S210 pH meter and a CamlaB from A Micro MOD200 Plus osmometer measured the pH and osmolality of the mixture (pH = 5.9; osmolality = 503 mOsm / L).
[0432] According to this method (2), two vials of 420 mg Reconstituted in 8.4 mL of milli-Q at 50 g / L, and homogenized using a vortex shaker at 1000 rpm for 5 minutes. The trastuzumab solution was then introduced into the Sartorius Vivaspin TM 20 centrifugal concentrators (polyethersulfone membrane; cut-off: 100 kDa) and centrifuged at 4000 rpm for 4 h. This allowed the trastuzumab antibody to be separated from the The excipients were separated from the commercial solution. The retentate was collected and analyzed by using Varian The concentration of trastuzumab was monitored by measuring the absorbance at 275 nm using a 50UV-Vis spectrophotometer. The trastuzumab concentration was readjusted to 200 g / L by adding milli-Q water, and the pH and osmotic pressure of the trastuzumab solution were measured (pH = 6.19; osmotic pressure = 129 mOsm / L).
[0433] In one method (2a), 2 mL of trastuzumab solution was introduced into a Luer lock syringe, and 2 mL of 3.3 / 6.7% solution was introduced into another Luer lock syringe. The two syringes were connected using a Luer lock connector, and the contents of one solution were repeatedly injected into the other solution and back again (about 200 times) to mix thoroughly. The pH and osmotic pressure of the solution were measured (pH = 5.77; osmotic pressure = 228 mOsm / L).
[0434] In another method (2b), 2 mL of trastuzumab solution and 2 mL of 3.3 / 6.7% solution were mixed thoroughly in a reactor by mechanical stirring at 100 rpm using a rotor with blades for 2 hours. The pH and osmotic pressure of the solution were measured (pH = 5.77; osmotic pressure = 243 mOsm / L).
[0435] Injection tests were performed using different needle diameters and 1 mL syringes to qualitatively assess the injectability of the solution. A score of 1 to 10 was given for the ability to be injected through the needle, and a score of 1 was given for very easy injection. The solution gelation test was also performed in a physiological serum solution to qualitatively assess the strength of the hydrogel formed. A score of 1 to 10 was given for the resistance of the gel in the medium, and a score of 10 was given for a very resistant gel. The results are shown in Table 2.
[0436]
[0437]
[0438] Table 2 - Qualitative estimates of injection and gelling capabilities for different needle diameters
[0439] These results suggest that even after purification of the trastuzumab originally contained in the commercially available The study also demonstrated that antibodies can be mixed with polymer solutions in different ways without affecting the injectability and gelation ability of the final solution.
[0440] Example 3: Preparation of a fluorescently labeled formulation MEX-CD2-I-tmb (also known as MEX-CD2-I-HER2) according to the present invention
[0441] According to method (3), polysaccharide B was chemically pre-labeled with cyanine 5.5 (Cy5.5). According to this method, trastuzumab was also chemically labeled with fluorescein by grafting with fluorescein isothiocyanate (FITC).
[0442] Labeling of polysaccharide B with cyanine 5.5 was achieved by adding the fluorophore directly to the modified chitosan solution. During the synthesis and purification steps, the solution was protected from light by aluminum foil. Briefly, a 5 g / L cyanine 5.5 solution was prepared by dissolving 100 mg of cyanine 5.5 in 20 mL of anhydrous DMSO.
[0443] Meanwhile, a solution of polysaccharide B was prepared by completely dissolving 1.1 g of polysaccharide B in 100 mL of milli-Q water. The pH of the solution was adjusted to pH = 6.02 by adding 750 μL of 1 mol / L NaOH solution under stirring. The cyanine 5.5 solution was added dropwise to the polysaccharide B solution under stirring at 200 rpm, so that one of the 27 free NH2 functional groups of polysaccharide B was grafted with a cyanine 5.5 molecule (molar ratio = 0.037). The reaction mixture was stirred at 100 rpm in the dark for 24 hours. Then, a 5.5 molecule was added to the polysaccharide B solution using a 5.5 molecule. The reaction mixture was stirred at 100 rpm in the dark for 24 hours. Slice PESU cassette (polyethersulfone membrane; cut-off: 100 kDa; filtration area: 200 cm 2)of The synthesized product was purified by tangential flow filtration using a Smart device according to the diafiltration-concentration model using 10 L of 5 mM acetic acid solution. The synthesized product was then lyophilized for 48 hours.
[0444] Trastuzumab labeled with fluorescein (sample 3a) was also labeled by adding the fluorophore directly to the sample from which the excipient had been previously removed. First, two vials of 420 mg Reconstituted in 8.4 mL of milli-Q at 50 g / L and allowed to stand at 4°C for 24 hours. The solution was then introduced into the Sartorius Vivaspin TM 20 centrifugal concentrators (polyethersulfone membrane; cut-off: 100 kDa) and centrifuged at 4000 rpm for 7 hours. The retentate was collected and purified by using a Varian The concentration of trastuzumab was monitored by measuring the absorbance at 275 nm using a 50UV-Vis spectrophotometer. The concentration of trastuzumab was measured to be 247 g / L.
[0445] A 5 g / L trastuzumab solution was then prepared by diluting 50 μL of the purified trastuzumab solution (compound 3b) in 1.95 mL of carbonate-bicarbonate buffer at pH = 9.06. At the same time, 1.9 mg of FITC was dissolved in 1.9 mL of anhydrous DMSO. The FITC solution was then added dropwise to the purified trastuzumab solution under stirring at 200 rpm, so that one trastuzumab molecule was grafted with 3.7 molecules of fluorescein. The reaction mixture was stirred at 200 rpm in the dark for 3 hours. The resulting solution was then introduced into Float-A- The resulting solution was placed in a dialysis tube (cut-off: 5 kDa) and dialyzed against 800 mL of 0.1 M phosphate buffer, pH = 7.4, for 18 hours. Finally, the resulting solution was dialyzed against 800 mL of milli-Q water for 2 hours.
[0446] According to the method, a viscous solution having a ratio of α / β% called composition 3.3 / 6.7% is prepared, wherein α is the mass concentration (w / w) of chitosan A, and β is the mass concentration (w / w) of polysaccharide B labeled with cyanine 5.5 (compound 3c). In brief, 667 mg of polysaccharide B (MEX-CD2) labeled with cyanine 5.5 and 333 mg of chitosan A are dispersed in 8.92 mL of milli-Q water, and 75 μL of ultrapure acetic acid are added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture is stirred for 2 hours until the medium is completely dissolved and homogenized. The obtained solution is recovered and introduced into a suitable fluid dispenser, and then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution comprising the composition. At the same time, a 3.3 / 6.7% solution (compound 3d) identical to that described in Example 2 is synthesized.
[0447] Fluorescently labeled MEX-CD2-I-tmb solution is finally prepared as follows: first, 0.9mL of 3.3 / 6.7% mixture (compound 3d) based on unlabeled polysaccharide B is introduced into a Luer lock syringe, and 0.1mL of 3.3 / 6.7% mixture made of polysaccharide B labeled by cyanine 5.5 is introduced into another Luer lock syringe. Two syringes are connected with Luer lock connectors, and by repeatedly injecting the contents of one into another and then inverting and thoroughly mixing (compound 3e). Meanwhile, 0.2mL of 5g / L fluorescein-labeled trastuzumab solution (compound 3a) is added to 0.8mL of the purified 247g / L trastuzumab (compound 3b) under stirring at 100rpm. Reclaim the resulting solution and inject into a suitable Luer lock syringe (compound 3f). The syringe containing compound 3e and the syringe containing compound 3f are finally connected with a Luer lock connector, and by repeatedly injecting a kind of content into another and then inverting (100 to 200 times) and thus thoroughly mixing. The pH values were measured using a Mettler Toledo SevenCompact S210 pH meter and a CamlaB Micro MOD200 Plus osmotic pressure (pH = 5.69; osmotic pressure = 285 mOsm / L).
[0448] The gelation and injection test of the solution was performed by direct injection into 0.9% (w / w) NaCl solution and 0.1M PBS (phosphate buffered saline) solution using a 1 mL syringe equipped with a 22G needle. The solution was easily injected by the operator and gelled immediately upon contact with physiological serum or PBS. In addition, the gel was qualitatively more resistant in PBS than in physiological serum.
[0449] Figure (2A) shows the in situ gelation of the MEX-CD2-I-tmb solution with fluorescence labeling, and Figure (2B) shows the gel obtained after complete gelation.
[0450] This study shows the possibility to easily and independently label polymers or antibodies with different fluorophore probes without significantly changing the physicochemical properties of the resulting solutions. The injectability and gelation capabilities of the resulting solutions are also comparable to those obtained without pre-labeling reagents.
[0451] Example 4: Study of the rheological properties of MEX-CD2-I solutions (before mixing with antibodies) as a function of pH and osmotic pressure (not according to the invention)
[0452] The aim of this study was to determine the physicochemical parameters of the precursor polymer solution (before mixing with the antibody) in which the compound remains stable in solution and does not cause significant gelation of the system. Therefore, 5% (w / w) solutions of MEX-CD2-I were prepared at different osmotic pressures and pHs, and their rheological properties were measured to establish the range of osmotic pressures and pHs that lead to gelation of the solution.
[0453] To prepare samples with osmotic pressure variation, a viscous solution of a composition called 1.7 / 3.3% with a ratio of α / β% was prepared, where α is the mass concentration of chitosan A (w / w) and β is the mass concentration of polysaccharide B (w / w).
[0454] Briefly, 1.67 g of polysaccharide B (MEX-CD2) and 0.83 g of chitosan A were dispersed in 47.33 mL of milli-Q water and 162 μL of ultrapure acetic acid was added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture was stirred for 2 hours until the medium was completely dissolved and homogenized. The resulting solution was collected and introduced into a suitable fluid dispenser and then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution containing the composition. The pH was measured using a Mettler Toledo SevenCompact S210 pH meter and a CamlaB from Micro MOD200 Plus osmometer measures pH and osmotic pressure of the mixture (pH=5.75; osmotic pressure=57mOsm / L). 2ml of the viscous solution is introduced into a suitable Luer lock syringe, and a certain mass of NaCl is introduced into another Luer lock syringe. The contents of one syringe are repeatedly injected into the contents of another syringe and vice versa using a Luer lock connector, and the contents of the two syringes are thoroughly mixed to obtain a sample with an osmotic pressure in the range of 57mOsm / L to 352mOsm / L at the same pH of 5.75.
[0455] To prepare samples with pH variations, samples were obtained from the same 1.7 / 3.3% solutions as described above.
[0456] Add 2 ml of this solution Float-A- Dialysis tubing (cut-off: 50 kDa). Prior to dialysis, the dialysis device was washed in a 10% (V / V) ethanol solution for 30 minutes and then in milli-Q water for 30 minutes.
[0457] Then, dialysis was performed against an isotonic NaCl solution (1.9 g / L NaCl, corresponding to an osmotic pressure of 57 mOsm / L) to maintain a stable concentration of the solution in the dialysis membrane throughout the experiment.
[0458] After 3 hours, the pH of the dialyzed solution was adjusted to pH=6.0 by adding NaOH and the solution was left for 18 to 72 hours, depending on the pH required for the sample. Samples with osmotic pressures ranging from 55 to 98 mOsm / L and pHs ranging from 5.75 to 6.4 were obtained.
[0459] The rheological properties of each sample were determined using a TA Instruments AR2000 rheometer. Specifically, measurements were performed using a 4° and 25 mm flat cone geometry. Prior to measurement, zero deviation was set and the inertial and rotational mapping of the instrument was calibrated. The sample was then spread out on the stage and the deviation from the geometry was set to 116 microns. Excess sample was removed with a scraper to limit edge effects.
[0460] A preliminary study was performed to determine the limits of the linear deformation domain of the material. To this end, a 10 Hz amplitude sweep was performed by varying the amplitude from 0.1% to 100% at an operating temperature of 25°C.
[0461] First, the storage modulus G' and loss modulus G" of each sample were measured at 25°C by 10% (6.9.10 -3 rad) at a fixed strain of 1 to 100 rad.s -1 The viscoelastic behavior of the solution and gel is then determined by scanning the oscillation frequency over a range of angular frequencies. G' and G" therefore define the viscoelastic behavior of the solution and gel. Then, without removing the sample from the pan, the sample was subjected to a 10 s -1 To 102s -1 The viscosity of each sample was measured by flow scanning studies at a scanning shear rate of . The storage modulus G' characterizes the elasticity of the material and increases during the gelation state of the system, and characterizes the flow behavior of the solution. The loss modulus G" characterizes the viscous behavior of the system. The results obtained on each sample are shown in Table 3. The materials are in a solution state (G">G') or a soft gel state (when G'>G').
[0462]
[0463]
[0464] Table 3 - Physicochemical and rheological properties of each sample
[0465] For samples with osmotic pressures below 352 mOsm / L, the storage modulus G' is lower than the loss modulus G". Therefore, above 350 mOsm / L, the system tends to be in a gelled state. When the moduli G' and G" are equal, the gelation point can be determined. At a pH of 5.75, the gelation point appears to occur at an osmotic pressure of approximately 300 mOsm / L. Therefore, gelation of the system with pH = 5.75 occurs when the osmotic pressure is above 300 mOsm / L.
[0466] Figure 3 The stability range of MEX-CD2-I solutions measured as a function of pH and osmolarity is summarized.
[0467] The results obtained on samples with different pH show inhomogeneity in the rheological properties, due to the inhomogeneity of the medium caused by the dialysis method used. However, for osmotic pressures ranging from 50 to 100 mOsm / L, a gelation of the system was qualitatively observed when the pH was above 6.4.
[0468] Example 5: Study of the physicochemical properties of MEX-CD2-I-tmb (also known as MEX-CD2-HER2) solutions as a function of trastuzumab concentration
[0469] The aim of this study was to determine the optimal concentration of trastuzumab in a MEX-CD2-I-tmb solution, which has physicochemical properties suitable for a subcutaneous injection of the product. Samples of MEX-CD2-I-HER2 containing 5% (w / w) polymer were prepared from commercial trastuzumab solutions ranging from 12.5 g / L to 75 g / L, purified with its excipients and unpurified with its excipients. For each sample, a Mettler Toledo SevenCompact S210 pH meter and a CamlaB The Micro MOD200 Plus Osmometer measures the pH and osmotic pressure of solutions.
[0470] Briefly, samples were prepared from a 3.3 / 6.7% viscous solution of the same composition as described in Example 2 (Sample 5a). Reconstituted to 100 g / L in 4.2 mL of milli-Q water and homogenized at 1000 rpm for 5 minutes using a vortex mixer. This solution is called trastuzumab solution with excipients (sample 5b). Two additional bottles of 420 mg of Reconstituted to 50 g / L in 8.4 mL of milli-Q water and homogenized using a vortex mixer at 1000 rpm for 5 minutes. The solution was then introduced into a Sartorius Vivaspin TM 20 centrifugal concentrator (polyethersulfone membrane; cut-off: 100 kDa) and purified using the same protocol described in Example 2. The resulting solution was diluted to 100 g / L with milli-Q water and was called excipient-free trastuzumab solution (Compound 5c).
[0471] MEX-CD2-I-tmb samples were prepared by introducing appropriate volumes of 3.3 / 6.7% solution into 2 mL Luer lock syringes. At the same time, different volumes of trastuzumab solution (purified or unpurified) were introduced into 2 mL Luer lock syringes to obtain final MEX-CD2-I-tmb solutions with trastuzumab concentrations of 12.5 g / L to 75 g / L. Two syringes were connected with Luer lock connectors and thoroughly mixed by repeatedly injecting the contents of one syringe into another syringe and then inverting (about 200 times). The pH and osmotic pressure of the solution were then measured.
[0472] For example, the synthesis of a 50 g / L sample of excipient unpurified trastuzumab was performed as follows: 1 mL of 3.3 / 6.7% solution was introduced into a 2 mL Luer lock syringe. 1 mL of unpurified trastuzumab solution (Compound 5b) was introduced into a 2 mL Luer lock syringe. The two syringes were connected with a Luer lock connector and the contents of one syringe were repeatedly injected into the other syringe and then back again (about 200 times) to mix thoroughly manually.
[0473] The results obtained for each sample are shown in Table 4.
[0474]
[0475] Table 4 - Physiological chemical properties of MEX-CD2-I-tmb solutions obtained from excipient purified or unpurified trastuzumab solutions as a function of trastuzumab concentration.
[0476] This study shows the biocompatibility of MEX-CD2-I-tmb solutions for subcutaneous injection as a function of trastuzumab concentration. For samples obtained from excipient-purified solutions, the pH as a function of trastuzumab concentration increases very slightly. This increase is due to the purified trastuzumab solution having a higher pH (pH = 6.19) than the 3.3 / 6.7% solution. Due to the contribution of the osmotic active substances contained in the trastuzumab solution, there is also an increase in osmotic pressure as a function of trastuzumab concentration. This trend is even more significant for samples obtained from unpurified trastuzumab solutions.
[0477] Example 6 - Study of the gelling capacity of solutions as a function of the MEX-CD2 / chitosan A ratio (not according to the invention)
[0478] The aim of this study was to determine the gelling capacity of MEX-CD2-I solutions as a function of the starting MEX-CD2 / chitosan A weight ratio. Solutions of 3.5 / 0%, 0 / 7%, and 2.5 / 2.5% were prepared according to the ratio α / β%, where α is the mass concentration (w / w) of chitosan A and β is the mass concentration (w / w) of polysaccharide B. For each sample, a Mettler Toledo Seven Compact S210 pH meter and a Camla B pH meter were used. The Micro MOD200 Plus Osmometer measures the pH and osmotic pressure of solutions.
[0479] In brief, 3.5 / 0% solution is prepared by dissolving 350mg chitosan A in 10mL milli-Q water in a 50mL reactor. Glacial acetic acid is added under mechanical stirring until a clear mixture is obtained in which all chitosan (100 μL) is dissolved. The mixture is placed under stirring for 2 hours until the medium is fully dissolved and homogenized. The solution obtained is reclaimed and introduced into a suitable fluid distributor (pH=5.64; osmotic pressure=101mOsm / L).
[0480] A 0 / 7% solution was prepared by dissolving 700 mg of MEX-CD2 in 10 mL of milli-Q water in a 50 mL reactor. Glacial acetic acid was added under mechanical stirring until a clear mixture was obtained in which all the chitosan (50 μL) was dissolved. The mixture was placed under stirring for 2 hours until the medium was completely dissolved and homogenized. The solution obtained was recovered and introduced into a suitable fluid dispenser (pH = 4.79; osmotic pressure = 157 mOsm / L).
[0481] A 2.5 / 2.5% solution was prepared by dissolving 250 mg chitosan A and 250 mg MEX-CD2 in 10 mL milli-Q water in a 50 mL reactor. Glacial acetic acid was added under mechanical stirring until a clear mixture was obtained in which the entire amount of polymer (80 μL) was dissolved. The mixture was stirred for 2 hours until the medium was completely dissolved and homogenized. The solution obtained was recovered and introduced into a suitable fluid distributor (pH=5.18; osmotic pressure=117 mOsm / L).
[0482] 300 μ L of each solution was injected into 20 mL of physiological serum solution (NaCl 9 g / l) or 20 mL of commercially available 10 mmol / L phosphate buffered saline (PBS) using a 1 mL syringe and a 25G needle. For each injection test, the gelation of the solution was qualitatively estimated after 30 minutes. The ability to inject through a 25G needle was assigned a score of 1-10, and a very easy injection score was 10. A score of 1 to 10 was also given for the resistance of the gel in the medium, and a very resistant gel score was 10. The results are shown in Table 5.
[0483]
[0484] Table 5 - Qualitative estimation of the injectability and gelling ability of MEX-CD2-I solutions according to the α / β % ratio.
[0485] The gelation of the solution in physiological serum solution is mainly due to the presence of MEX-CD2 in the solution. In PBS, chitosan A tends to precipitate and form a very soft gel with little cohesion, but still contributes to the gelation of the system. Solutions with a high proportion of MEX-CD2 will have a greater tendency to gel easily, while chitosan is added to obtain crystallinity regions as described in previous patent application FR 2110474.
[0486] Example 7: Preparation of the formulation MEX-CD2-I-HER2 (also referred to as MEX-CD2-tmb) according to the present invention according to method (4)
[0487] 7.1. General preparation process of MEX-CD2-I-HER2 according to method (4)
[0488] According to method (4), the preparation of MEX-CD2-I-HER2 is carried out from a viscous solution of a composition called 3.3 / 6.7% MEX-CD2-I solution in the ratio α / β%, where α is the mass concentration (w / w) of chitosan A in the formulation under consideration and β is the mass concentration (w / w) of polysaccharide B in the formulation under consideration.
[0489] Briefly, 667 mg of polysaccharide B (MEX-CD2) and 133 mg of chitosan A were dispersed in 8.92 mL of milli-Q water and 72 μL of ultrapure acetic acid was added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture was stirred for 2 hours until the medium was completely dissolved and homogenized. The resulting solution was recovered and introduced into a suitable fluid dispenser and then centrifuged at 4000 rpm for 10 minutes at room temperature to obtain a bubble-free solution containing the composition. The mixture was then introduced into a glass syringe and sterilized in an autoclave at 121°C for 20 minutes. The pH was measured using a Mettler Toledo SevenCompact S210 pH meter and a CamlaB from The pH and osmotic pressure of the mixture were measured with a Micro MOD200 Plus osmometer (pH = 5.7; osmotic pressure = 410 mOsm / L). The Newtonian viscosity of the resulting solution was measured with a ThermoScientific HAAKE RheoStress 600 sensor system using a C35 / 2° Ti L conical plate geometry. -2 Up to 10 3 s -1 The viscosity was measured by a flow scanning linear study with a scanning shear rate of 1.5 Å. For each value, 10 points were recorded per decade with a measuring time of 10 s. The Newtonian viscosities of the solutions before and after sterilization were η0 = 2023 Pa.s and η0 = 3260 Pa.s, respectively.
[0490] According to this method (4), a vial of 420 mg Reconstituted in 2.1 mL of milli-Q at 200 g / L, trastuzumab was placed at 4°C for 24 hours until complete dissolution and homogenization were achieved.
[0491] According to the method (4), 1.2 mL of trastuzumab solution is introduced into a Luer lock syringe, and 1.2 mL of 3.3 / 6.7% solution is introduced into another Luer lock syringe. Two syringes are connected using a Luer lock connector, and the contents of one solution are repeatedly injected into the other solution and then back (about 50 to 200 times) to mix thoroughly. The pH, osmotic pressure and Newtonian viscosity of the solution are measured (pH = 5.81; osmotic pressure = 564mOsm / L; η0 = 126.7Pa.s). The injectability of the MEX-CD2-I-HER2 solution is accurately measured using a Shimadzu AG-X force machine. The solution is introduced into a BD Hylok 400 equipped with a Terumo Agani 25G needle (0.5×16mm). TM1 mL pre-filled glass syringes. Syringability was determined by the Newton force required to eject the solution at a constant plunger speed of 1 mm / s. e =46.7N injection force, which means that the system can be manually injected by a practicing physician (TERobinson et al., Filling the Gap: A Correlation between Objective and Subjective Measures of Injectability, Adv. Healthc. Mater., vol. 9, no 5, p. 1901521, 2020).
[0492] The gelation test of the solution was performed by direct injection into 10 mM PBS (phosphate buffered saline) solution using a 1 mL syringe equipped with a 25G needle. The solution gelled immediately upon contact with PBS.
[0493] 7.2. Preparation of Gadolinium-labeled MEX-CD2-I-HER2
[0494] According to the following method, gadolinium Gd 3+ Complexation of ions on chelating groups pre-grafted onto polysaccharide B, which is chemically labeled with gadolinium.
[0495] Labeling of polysaccharide B with gadolinium was achieved by adding a 1 mol / L gadolinium solution directly to the modified chitosan solution. Briefly, 8.74 mL of 1 mol / L Gd 3+ The solution was added to 1 L of 7 g / L polysaccharide B solution under stirring. The pH was then adjusted from pH = 3.6 to pH = 5.6 by adding 1 mol / L sodium hydroxide solution. The solution was stirred at 60°C for 48 hours. Slice PESU cassette (polyethersulfone membrane; cut-off: 100 kDa; filtration area: 200 cm 2 )of The synthesized product was purified by tangential flow filtration using a diafiltration-concentration model using 10 L of 5 mM acetic acid solution using a Smart device. The synthesized product was then freeze-dried for 48 hours. The product was analyzed by ICP-MS performed on a PerkinElmer NexION 2000. 158 The Gd analysis measured the amount of gadolinium complexed to the grafted chelating groups of polysaccharide B and was estimated to be 70% of the total DOTAGA groups complexed with gadolinium.
[0496] According to the method, a viscous solution called composition 3.3 / 6.7% with a ratio of α / β% is prepared, wherein α is the mass concentration (w / w) of chitosan A, and β is the mass concentration (w / w) of total polysaccharide B (comprising unmodified compounds and Gd labeled compounds). In brief, 601.9 mg polysaccharide B, 66.2 mg gadolinium-labeled polysaccharide B and 332.9 mg chitosan A are dispersed in 8.92 mL milli-Q water, and 76 μL ultrapure acetic acid is added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture is stirred for 2 hours until the medium is completely dissolved and homogenized. The obtained solution is recovered and introduced into a suitable fluid dispenser, and then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution comprising the composition. The mixture is then introduced into a glass syringe and sterilized in an autoclave at 121 ° C for 20 minutes.
[0497] According to this method, a vial of 420 mg Reconstituted in 2.1 mL of milli-Q at 200 g / L, trastuzumab was placed at 4°C for 24 hours until complete dissolution and homogenization were achieved.
[0498] According to this method, 1 mL of trastuzumab solution is introduced into a Luer lock syringe, and 1 mL of 3.3 / 6.7% solution is introduced into another Luer lock syringe. The two syringes are connected using a Luer lock connector and mixed thoroughly by repeatedly injecting the contents of one solution into the other and back again (about 50 to 200 times).
[0499] 7.3. Preparation of MEX-CD2-I-HER2 labeled with fluorescent and gadolinium markers
[0500] Polysaccharide B was chemically pre-labeled with cyanine 5.5 (Cy5.5) according to the following method. According to this method, gadolinium Gd 3+ Complexation of ions on chelating groups pre-grafted onto polysaccharide B Polysaccharide B was chemically labeled with gadolinium.
[0501] Labeling of polysaccharide B with cyanine 5.5 was achieved using the same procedure as described in Example 3.
[0502] Labeling of polysaccharide B with gadolinium was achieved using the same method as described in Example 7.2.
[0503] According to the method, a viscous solution called composition 3.3 / 6.7% with a ratio of α / β% is prepared, wherein α is the mass concentration (w / w) of chitosan A, and β is the mass concentration (w / w) of total polysaccharide B (comprising unmodified compounds, Cy5.5-labeled compounds and Gd-labeled compounds). In brief, 318 mg polysaccharide B, 7.63 mg polysaccharide B labeled with cyanine 5.5, 17.2 mg polysaccharide B labeled with gadolinium and 167.5 mg chitosan A are dispersed in 4.46 mL milli-Q water, and 38 μL ultrapure acetic acid is added in a 50 mL reactor under mechanical stirring at 100 rpm. The mixture is stirred for 2 hours until the medium is completely dissolved and homogenized. The solution obtained is recovered and introduced into a suitable fluid distributor, then centrifuged at 4000 rpm for 10 minutes to obtain a bubble-free solution comprising the composition. The mixture is then introduced into a glass syringe and sterilized in an autoclave at 121 ° C for 20 minutes.
[0504] According to this method, a vial of 420 mg Reconstituted in 2.1 mL of milli-Q at 200 g / L, trastuzumab was placed at 4°C for 24 hours until complete dissolution and homogenization were achieved.
[0505] According to this method, 0.5 mL of trastuzumab solution is introduced into a Luer lock syringe, and 0.5 mL of 3.3 / 6.7% solution is introduced into another Luer lock syringe. The two syringes are connected using a Luer lock connector and mixed thoroughly by repeatedly injecting the contents of one solution into the other and vice versa (about 50 to 200 times).
[0506] Example 8: In vivo study of MEX-CD2-I-tmb (also called MEX-CD2-I-HER2 solution) according to the present invention
[0507] Unless otherwise stated, the MEX-CD2-I-tmb solution used in this example was prepared according to Example 1.
[0508] 8.1. In vivo toxicity studies
[0509] 16 mice were subcutaneously injected (in the neck) with 200 μL of MEX-CD2-I solution (not according to the present invention), and 9 mice were subcutaneously injected with 250 μL of MEX-CD2-I-tmb solution prepared according to Example 1 loaded with 100 g / L trastuzumab antibody (corresponding to a dose of 15 mg anti-HER2 antibody).
[0510] The weight of the mice was monitored. The results showed that no gross toxicity occurred in the mice. Figure 4Shown is the weight measurement after subcutaneous injection of 200 μL of MEX-CD2-I-HER2 solution loaded with 100 g / L trastuzumab antibody.
[0511] Hematoxylin and eosin (H&E) immunohistochemistry was performed on three mice 20 days after injection. Figure 5 No cell recruitment (macrophages) was observed, confirming the absence of inflammation.
[0512] 8.2. In vivo study of sustained release of antibodies through hydrogels
[0513] For this study, we quantitatively compared the presence of anti-HER2 antibody (trastuzumab) released from its in situ formed hydrogel in plasma 20 days after subcutaneous injection of 200 μL of MEX-CD2-I-tmb solution loaded with 100 g / L trastuzumab antibody (corresponding to a dose of 15 mg trastuzumab antibody) with that after subcutaneous injection of 200 μL of MEX-CD2-I-tmb solution loaded with 100 g / L trastuzumab antibody (corresponding to a dose of 15 mg trastuzumab antibody) by HTRF (homogeneous time-resolved fluorescence). Controlled release of the same antibody after SC formulation (corresponding to a dose of 15 mg trastuzumab antibody per injection).
[0514] Nine mice per group were used in this study, and blood samples were collected from three mice every three days. Figure 6 shown.
[0515] The results showed that using our MEX-CD2-I-tmb solution, the maximum presence (C max ) from 1 day ( In addition, at the end of this experiment (day 26 after SC injection), no trace of hydrogel was present at the injection site, confirming the biodegradability of the formulation.
[0516] 8.3. In vivo study of biodegradability of hydrogels
[0517] The polymer was functionalized with a cyanine 5.5 fluorescent probe to track its biodegradation after subcutaneous injection. 200 μL of this fluorescently labeled MEX-CD2-I-tmb prepared according to Example 3 was injected into 3 mice and longitudinally monitored every 3 days by whole body fluorescent imaging (IVIS, PerkinElmer).
[0518] The results are as follows Figure 7 shown.
[0519] For this formulation of cyanine 5.5-labeled hydrogels, we observed a stable signal plateau for up to 26 days after implantation, confirming the possibility of modifying the hydrogel formulation to extend its subcutaneous longevity.
[0520] Example 9: In vivo biodegradability and toxicity study of the MEX-CD2-I-HER2 solution according to the present invention
[0521] 9.1. In vivo biodegradability studies by fluorescence
[0522] The MEX-CD2-I-HER2 solution was prepared according to the method of Example 7.3.
[0523] Part of the MEX-CD2 used in the preparation was labeled with cyanine 5.5 (Cy5.5) fluorescent dye, and the other part was labeled with gadolinium ion Gd 3+ Complexation. 150 μL of the final solution loaded with 100 g / L trastuzumab was injected into nude mice (n=3). Fluorescence images and bright field images were collected by back-illuminated CCD cooling camera ORCAIIBT-512G (Hamamatsu Photonics Deutschland GmbH, Herrsching am Ammersee, Germany) using a colored glass long-pass RG 665 filter (Melles Griot, Voisins les Bretonneaux, France). Light excitation was performed at 633 nm and the emission wavelength was detected at 680 nm. The exposure time was set to 30 s for optical imaging and 0.05 s for bright field imaging. Fluorescence images were collected at different time points to monitor the loss of fluorescence over time, resulting in degradation of the hydrogel.
[0524] The results are as follows Figure 8 and Fig. 9 shown.
[0525] After 8 days, approximately 55% of the initial fluorescence intensity was observed, which means that the hydrogel formed during this period was significantly degraded.
[0526] 9.2. In vivo biodistribution studies by ICP-MS
[0527] Following the experiment detailed in section 9.1., mouse organ slices were collected after dissection (21 days after injection) and then mineralized with concentrated nitric acid in a Multiwave 5000 from Anton Paar. The organs were separated and digested according to their weight to ensure uniformity of digestion throughout the method. All digestions and sample preparations used standard 69% HNO3 [ROTIPURAN Supra provided by Roth] and ultrapure (18.2MΩcm) water. The reactor was cleaned before and after the sample cycle using a programmed cleaning method (4mL water and 6mL 69% HNO3, 0 to 180°C ramp for 10 minutes, 180°C for 10 minutes). Rinse with ultrapure water after the cycle. Using the bioorganic digestion method, the samples were digested under the following parameters: 69% HNO3, 0 to 100°C ramp for 10 minutes, 100°C for 10 minutes, 100 to 200°C ramp for 10 minutes and 200°C for 10 minutes (40 minute cycle).
[0528] ICP-MS analysis was performed on a PerkinElmer NexION 2000 inductively coupled plasma mass spectrometer (ICP-MS). Before use, the machine was continuously cleaned with 10% HNO3 for 20 minutes and then with 1% HNO3 for 1.5 hours. All system parameters were optimized before starting the analysis according to the machine manual (mass calibration, torch alignment, QID in mode KED and standard, nebulizer gas flow and dual detector calibration). Once all parameters were optimized, a final performance check was performed in the standard and KED. An internal standard of 2ppb indium was used in all ICP samples to ensure consistent measurement and reliability. The base solvent consisted of 0.5% HNO3, 0.7% tert-butanol and water. The addition of tert-butanol helps to minimize the matrix effect of carbon because the degradation of the sample includes proteins and other carbon-heavy biomolecules. Gadolinium (158Gd) was analyzed.
[0529] The results are shown in Fig.10 .
[0530] Twenty-one days after injection, about 40% of the hydrogel was present in the injection area and about 20% was present in the kidney, highlighting the elimination pathway of the hydrogel after degradation. The hydrogel that remained in the injection area was a form of the hydrogel that had been degraded that was slightly adherent to the neck tissue.
[0531] 9.3. In vivo biodegradability studies by MRI
[0532] The MEX-CD2-I-HER2 solution was prepared according to the method of Example 7.2.
[0533] The MEX-CD2 used in this formulation has some 3+Pre-grafted chelating agent of ion complexation.200 μ L of this Gd-complexed MEX-CD2-I-HER2 solution was injected into the neck region of 3 mice, and 40 μ L was injected into another 3 mice to evaluate the degradability characteristics according to the volume of gel applied.200 μ L of antibody-free solution (not according to the present invention) was also injected into 3 mice to evaluate the degradability characteristics with and without antibody loading. In addition, before mixing with the antibody solution with ratio α / β%, 2 / 4% and 0 / 10% viscous solution were used as precursor solution to prepare drug-loaded solution according to the method explained in Example 7.2, wherein α is the mass concentration (w / w) of chitosan A, and β is the mass concentration (w / w) of total polysaccharide B (comprising unmodified compound and Gd-labeled compound).For each solution, these solutions were injected (200 μ L) into the neck of 3 mice respectively.
[0534] The results are shown in Fig.11 .
[0535] The hydrogels formed from the MEX-CD2-I-HER2 solution (loaded with antibodies) showed different t values when compared to the hydrogels formed from the reference solution without antibody loading (not according to the present invention). 1 / 2 values (30 vs. 20 dd) and strongly different T1 values (ca 500 ms vs. ca. 250 ms, respectively). The presence of trastuzumab affected both size reduction and T1 changes.
[0536] Even if the same volume was injected, the scaffold obtained from the 3% antibody-loaded polymer solution had a lower initial volume than the other scaffolds. This may be due to the higher water content that was reabsorbed immediately after administration. Its size decreased rapidly (t 1 / 2 The decrease in scaffold concentration (from 5% to 3%) affected the size reduction and T1 change.
[0537] Scaffolds obtained from polymer solutions consisting of polysaccharide only (ie from 0 / 10% polymer precursor solution) showed an initial size increase followed by very rapid disappearance from the injection site. At t=3 days, the scaffold was no longer present. Changes in scaffold composition affected size reduction and T1 changes.
[0538] Therefore, the hydrogel scaffold obtained from the MEX-CD2-I-HER2 solution appears to be the scaffold with the best formulation. The presence of trastuzumab accelerated water filling (as detectable in the T1 changes, as well as in the T 1w and T 2w Inhomogeneous signal in MRI).
[0539] Furthermore, the results obtained for other formulations demonstrated the ability to tune the hydrogel scaffold formed after injection as desired, and thus the release of the captured protein (here trastuzumab).
[0540] 9.4. Conclusions on biodegradability
[0541] Importantly, once normalized, the volume injected did not perturb the degradation kinetics of the hydrogel. Thus, subcutaneous implantation of 50 μL and 200 μL of hydrogel-loaded trastuzumab (n=3) provided comparable Fig.12 The same degradation curves are shown.
[0542] 9.5. Research on inflammatory cells (neutrophils)
[0543] The MEX-CD2-I-HER2 solution used in this example was prepared according to the method detailed in Example 7.1.
[0544] Ex vivo quantification of IL6, TNFa and mub-40 levels was evaluated by cell counting of digested samples at 24 hours and 120 hours after implantation (n=3 per group). The results were compared with negative controls (untreated) and positive controls (neutrophils pre-activated with LPS) (data not shown). Mild inflammation was initially observed after implantation, i.e., an increase in the amount of pro-inflammatory neutrophils localized to the injection site and an increase in TNFα levels. However, on the 5th day after implantation, the total amount of pro-inflammatory neutrophils was significantly reduced back to the basal level, as well as TNFα. The cytokine IL6 was low on the 1st day and increased on the 6th day (2.5% and 13%). However, these levels were significantly lower than those of positively activated neutrophils (54%), confirming the biocompatibility of the hydrogel formulation.
[0545] The absence of pro-inflammatory neutrophils at the implantation site was further verified by immunofluorescence staining with anti-mub40 antibody (day 5 after implantation, n=3).
[0546] The results are shown in Fig.13 .
[0547] 9.6. Conclusions on the safety profile of hydrogel-loaded monoclonal antibody formulations
[0548] The results show that the presence of the gel under the skin induces no inflammation / much less inflammation than prior art gels such as gels containing alginate therein.
[0549] Example 10: In vitro study of the release of various proteins from hydrogels
[0550] Materials and methods
[0551] The MEX-CD2-1 solution used in the present embodiment is prepared according to Example 7.1, except that the solution loads trastuzumab (Roche), rituximab (Roche), trastuzumab, HER2 Fab'2, HER2 VHH. The mixture of the solution is prepared overnight, and the sample is then placed in a 1mL Eppendorf tube filled with PBS. At each time point, aliquots are harvested from the environment and fresh PBS is added to the solution. Bradford is carried out to determine the amount of protein in each aliquot, thereby quantifying the amount of antibody / fragment / protein.
[0552] 10.2. Results
[0553] Fig.14 Results are shown for the cumulative release of monoclonal antibodies alone (trastuzumab or rituximab) and combinations of monoclonal antibodies (trastuzumab and pertuzumab) in PBS at 37°C.
[0554] Fig.15 Results are shown for the cumulative release of monoclonal antibody fragments (FaB'2 and VHH) in PBS at 37°C.
[0555] Example 11: SEM imaging of the formulation MEX-CD2-I-HER2 according to the present invention A MEX-CD2-I-HER2 solution was prepared according to the method of Example 7.2.
[0556] The MEX-CD2 used in this formulation has some 3+ Ion complexed its pre-grafted chelator.500 μ L of this Gd complexed MEX-CD2-I-HER2 solution is injected into 100 mL of 10 mmol / L PBS solution (phosphate buffered saline).500 μ L of antibody-free solution (not according to the present invention) in 100 mL of 10 mmol / L PBS solution is also injected to further evaluate the impact of antibody loading on the surface morphology of the hydrogel formed by SEM imaging.Two solutions are injected with a Terumo agani25G × 16mm needle with an inner diameter of 284 μ m measured by an optical microscope.After gelation for 1 hour, PBS is replaced by 100 mL of 10% (V / V) EtOH / H2O solution.Solution is replaced by another solution per hour, and its ratio in ethanol increases by 20% (V / V) until 100% EtOH.Then the sample is subjected to critical point drying including 12 cycles of 120s at 18 ° C to change gaseous CO2 from 100% EtOH. The resulting dehydrated hydrogel was then placed on a metal STUB and metallized by depositing a thin layer of 10 nm copper on the surface of the polymer scaffold. The obtained scaffolds were observed with a SEM FEIQUANTA 250FEG at 2 kV or 3 kV.
[0557] The results are shown in Fig.16 .
[0558] The gel diameter measured in both cases (average 260 μm) was slightly lower than the inner diameter of the needle used for injection (284 μm). The hydrogel scaffolds obtained with the solution loaded with trastuzumab highlighted a significantly thicker network than the scaffolds obtained from the solution without antibody. In the presence of a highly antibody-concentrated medium, a rougher network was obtained by gelation of the system. This difference in surface morphology demonstrates the ability of the gel to capture the drug and release the drug after gelation.
Claims
1. A pharmaceutical preparation of a pharmaceutically active protein, comprising: - an effective amount of a protein or a combination of proteins, - chitosan A comprising 90 to 100 mol % of D-glucosamine and 0 to 15 mol % of N-acetyl-D-glucosamine, - at least one statistical polysaccharide B comprising D-glucosamine, N-acetyl-D-glucosamine and at least one sugar unit of formula I: in: Rc is a hydrophilic group, Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, and - one or more pharmaceutically acceptable excipients.
2. The pharmaceutical preparation according to claim 1, wherein Rc is a group having an acidic nature, typically selected from a group comprising a carboxyl group (-COOH), a sulfonic acid group (-SO2OH), a phosphonate group (-PO(OH)2), a thiol group (-SH), an alcohol group (-OH) and a group comprising a chelating agent.
3. The pharmaceutical composition according to claim 1, wherein the statistical polysaccharide B has the general formula II: in: Rc is a hydrophilic group, Z is a linker which is a single bond, a hydrocarbon chain containing 1 to 12 carbon atoms, the chain being linear or branched, saturated or unsaturated, and optionally containing one or more heteroatoms preferably selected from nitrogen, oxygen and sulfur, x is 0.01 to 0.5, y is 0.05 to 0.5, The ratio y / x is greater than 0.2, preferably greater than 1, The sum of x+y is greater than 0.
1.
4. A pharmaceutical formulation according to any one of the preceding claims, wherein the formulation has a viscosity of 10 to 500 Pa.s, as measured by rotational rheometry in a flat cone geometry at room temperature at 0.001 s -1 To 0.01s -1 , for example 0.001s -1 To 0.01s -1 , especially 0.01s -1 Shear rate measurement.
5. The pharmaceutical formulation according to any one of the preceding claims, wherein the pH of the formulation is from 5.0 to 6.5, preferably from 5.5 to 6.
0.
6. The pharmaceutical formulation according to any one of the preceding claims, wherein the formulation has an osmotic pressure of 50 to 600 mOsm / L, preferably 100 to 600 mOsm / L, more preferably 250 to 450 mOsm / L, or 50 to 300 mOsm / L, preferably 50 to 250 mOsm / L.
7. A pharmaceutical formulation according to any one of the preceding claims, comprising: - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A, and 10 to 200 g / l, preferably 20 to 100 g / l of polysaccharide B, and - 1 g / l to 200 g / l, preferably 50 to 100 g / l of protein or a combination of proteins.
8. The pharmaceutical formulation according to any one of the preceding claims, wherein the protein has a molecular weight of 10 kDa to 250 kDa, preferably 20 kDa to 250 kDa, preferably 100 kDa to 250 kDa, preferably 120 kDa to 250 kDa, preferably 150 kDa to 250 kDa.
9. The pharmaceutical formulation according to any one of the preceding claims, wherein the protein or protein combination is selected from the group consisting of antibodies, enzymes, fusion proteins and combinations thereof.
10. The pharmaceutical formulation according to any one of the preceding claims, wherein the protein or combination of proteins comprises an antibody or an antigen-binding fragment of an antibody.
11. The pharmaceutical formulation according to claim 10, wherein the antibody is selected from the group consisting of trastuzumab, rituximab and pertuzumab or a combination thereof.
12. The pharmaceutical formulation according to any one of the preceding claims, further comprising at least one pharmaceutically acceptable excipient selected from solvents, stabilizers, surfactants, buffers, antimicrobial preservatives, protectants, antioxidants, chelating agents and fillers.
13. A pharmaceutical formulation according to any one of the preceding claims, wherein the formulation comprises: 1 g / l to 200 g / l, preferably 50 to 100 g / l of an antibody or a combination of antibodies, in particular trastuzumab, rituximab, pertuzumab or daratumumab, or a combination of trastuzumab and pertuzumab, - 5 to 200 g / l, preferably 10 to 200 g / l, more preferably 10 to 150 g / l of chitosan A, and 20 to 400 g / l, preferably 20 to 300 g / l of statistical polysaccharide B, and at least one excipient selected from the group consisting of: - 1 to 100 mM buffer providing a pH of 5.5-6.5, preferably L-histidine hydrochloride monohydrate; -1 to 500 mM of a stabilizer, preferably α,α-trehalose dihydrate -5 to 25 mM antioxidant, preferably methionine.
14. A kit, characterized in that It contains: - at least one first container containing chitosan A and a statistical polysaccharide B as defined in any one of claims 1 to 3, - at least one second container containing a protein or a combination of proteins as defined in any one of claims 8 to 11.
15. A pharmaceutical formulation according to any one of claims 1 to 13 or a kit according to claim 14 for use in the treatment of cancer, typically breast cancer or gastric cancer.
